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Histone deactylase inhibitors (HDACi) are a new class of anticancer therapeutics; 
however, little is known about HDACi or the individual contribution of HDAC isoform 
activity in soft tissue sarcoma (STS). We investigated the potential efficacy of HDACi 
as monotherapy and in combination with chemotherapy in a panel of genetically 
complex STS. We found that HDACi combined with chemotherapy significantly 
induced anti-STS effects in vitro and in vivo. We then focused our study of HDACi in 
malignant peripheral nerve sheath tumor (MPNST), a subtype of highly aggressive, 
therapeutically resistant, and commonly fatal malignancies that occur in patients with 
neurofibromatosis type-1 (NF1) or sporadically. The therapeutic efficacy of HDACi was 
investigated in a panel of NF1-associated and sporadic MPNST cell lines. Our results 
demonstrate the NF1-assocaited cohort to be highly sensitive to HDACi while sporadic 
cell lines exhibited resistance. HDACi-induced productive autophagy was found to be 
a mode of resistance and inhibiting HDACi-induced autophagy significantly induced 
pro-apoptotic effects of HDACi in vitro and in vivo. HDACs are not a single enzyme 
consisting of 11 currently known isoforms. HDACis used in these studies inhibit a 
variety of these isoforms, namely class I HDACs which include HDAC1, 2, 3, and 8. 
Recently, HDAC8-specific inhibitors (HDAC8i) have been created and tested in 
v 
various cancer cell lines. Lastly, the potential therapeutic efficacy of HDAC8i was 
investigated in human (NF1-associated and sporadic) and NF1-associated murine-
derived MPNST. HDAC8i abrogated cell growth in human and murine-derived MPNST 
cells. Similar to the pattern noticed with pan-HDACis NF1-associated cells, especially 
murine-derived, were more sensitive to HDAC8i compared to human sporadic MPNST 
cell lines. S-phase arrest was observed in human and murine MPNST cells, 
independent of p53 mutational and NF1 status. HDAC8i induced apoptosis is all cell 
lines tested, with a more pronounced effects in human and murine-derived NF1-
associated cells. Most importantly, HDAC8i abrogated murine-derived MPNST 
xenograft growth in vivo. Taken together, these findings support the evaluation of pan-
HDACi and isoform-specific inhibitors as a novel therapy to treat MPNST, including in 
combination with autophagy blocking combination regimens in particular for patients 
with sporadic MPNST. 
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Figure 1. Anatomic distribution of 
sarcomas. Sarcomas can arise 
anywhere in the human body. This data 
is from UTMDACC Sarcoma Surgical 
Database (1996–2005).  Modified from 
Figure 3, Lahat et al. Surg Clin N Am  
2008 88,451–481. 
Chapter I: Introduction 
Section 1: Genetically complex soft tissue sarcoma (STS) 
1.1 Epidemiology and etiology  
      “Cancer” as a disease has been described and treated with methods of the time 
that date back to ancient Egypt around 1500 B.C. In the campaign against cancer it is 
important to identify that malignant disease is not a single entity. Sarcoma and 
carcinoma make up most solid tumors; however, sarcoma is not equal to carcinoma. 
Sarcomas are heterogeneous tumors that are different from other cancers based on 
their germ layer origin, sarcoma arises 
from mesenchymal tissues and carcinoma 
arise epithelial tissues (1). Sarcoma is 
divided into sarcoma of the bone and soft 
tissue sarcoma (STS) which entail 
numerous subclasses based on the tissue 
of origin. STS have a ubiquitous 
distribution throughout the body with a 
higher propensity to develop in the lower 
extremities (Fig. 1). STS constitute 1% of 
all adult cancers and occur at a higher 
frequency in children at about 15% of all 
neoplasms. The incidence of this disease 
is about 10 – 12,000 new cases per year in 
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the US; where about 4,000 of these patients succumb to the disease (1). According to 
the Surveillance Epidemiology and End Results (SEER) database the incidence ratio 
of STS men are more likely to develop the disease compared to women (2). Relative 
to other cancers; not much is known about the epidemiology of STS (2). Sarcomas in 
general are a main cause of neoplastic-related deaths throughout the first two decades 
of life and account for the 5th leading cause of in men under 20 years old and the 4th 
leading cause of malignancy-related deaths in women under 20 years of age (3).  
STS are believed to arise spontaneously with little known about causes of the disease. 
In rare occasions inherited conditions are known to predispose some individuals to 
developing STS. One such condition, Li-Fraumeni syndrome comprises a TP53 gene 
(encodes the protein p53) mutation potentially leading to the predisposing of malignant 
disease (4, 5). Retinoblastoma is a malignancy initiated by a mutation in the RB1 
gene. Mutation of this tumor suppressor may occur spontaneously or hereditarily (6, 
7). The loss of tumor suppressor NF1 is a common feature in patients with MPNST. 
NF1 loss can occur under heritable or spontaneous conditions. While NF1 loss is a 
major driving force for the development of MPNST, this malignancy can develop in 
patients without NF1 (8, 9). As it is known to be a risk for the development of many 
cancers, ionizing radiation increases the risk for the future development of MPNST. It 
is well documented that women previously treated with radiation for breast cancer, 
have a high chance of developing angiosarcoma (10). In light of these potential risk 
factors, individuals diagnosed with STS have >15% risk of developing a second cancer 
in the future.  
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Figure 2. Cross-section of leg showing sarcoma 
differentiation. Sarcomas show recognizable 
differentiation from normal mesenchymal tissues. 
Some sarcomas lack recognizable differentiation 
from any mesenchymal tissue, such as Ewing’s 
sarcoma and synovial sarcoma. Modified from Figure 
1, Lahat et al. Surg Clin N Am  2008 88,451–481. 
  
 
 
1.2 Biological features of STS; patterns of disease 
 
The biological behavior of STS is exceedingly variable. The histological grade of the 
tumor is a major prognosticator on the behavior of the disease. Mitotic count, 
cellularity, necrosis, differentiation, and stromal content are factors used to determine 
histological grade (11). Low grade STS have low mitotic rates with a low risk of 
metastatic disease, however, these low grade tumors have a high risk for local 
recurrence (12). High grade STS have a high mitotic rate, exhibit invasiveness to local 
tissue and have a high risk of metastatic spread. For patients with high grade STS, 
metastatic disease most commonly occurs in the lungs. While lung metastases 
commonly arise from primary tumors of the extremities, they can occur from nearly any 
primary site or histology (12, 13).  
 
1.3 Histological classification 
 
As previously alluded to, STS 
is not a single entity and 
comprises about 50 
histological subtypes (14) 
(Fig. 2). Sarcomas are 
molecularly grouped into two 
cohorts: sarcomas with 
specific reciprocal 
translocations and relatively 
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simple karyotypes, and sarcomas with complex, unbalanced karyotypes, with no 
specific translocations. Simple karyotypic sarcomas make up about 1/3 of all sarcomas 
with 15 of these sarcomas of various histologies. These simple karyotypic sarcomas 
possess over 25 different translocations with a majority of the derived fusion genes 
creating aberrant chimeric transcription factors with the latter producing aberrant 
kinases (2). These translocations biologically translate into transcriptional deregulation 
or aberrant signaling which entail an important determinant toward a specific therapy. 
Complex karyotypic sarcomas make up about 2/3 of all sarcomas in adults with a 
dynamic biology consisting of aberrations such as genetic gains and losses, 
chromosomal instability, and telomere dysfunctions. Diagnostically, the fusion genes of 
simple karyotypic sarcomas make for excellent molecular markers whereas complex 
karyotypic sarcomas; due to their multiple aberrations do not have bona fide diagnostic 
molecular markers.  
1.4 Diagnosis and Treatment 
STS is typically diagnosed in individuals at a median age of 56 years of age. A small 
percentage (about 10%) of patients less than 20 years of age are diagnosed with STS 
where patients over 55 years of age make up about 50% of STS diagnoses (2). The 
signs and symptoms of STS are not specific where most patients present with a 
painless and palpable mass. In a third of the presented cases, STS-induced pain is 
observed (15). Sarcomas growing in the abdominal and pelvic cavities may progress 
undetected over long periods of time barring symptoms resulting in a delayed 
diagnosis.  Timely diagnosis and referral are advantageous, as the size of the tumor at 
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presentation is an incessant variable for the possibility of recurrence and metastasis 
(15). 
To date, STS are typically treated using a multidisciplinary approach which includes 
surgery, chemotherapy, and radiation. As we continue to grasp a better 
comprehension on the diverse natural history, biology, and therapeutic response of 
STS; personalized therapy based on histology will be commonplace. Currently, 
surgical resection occasionally supplemented with radiotherapy, of the tumor remains 
the mainstay of therapy. While surgery and radiotherapy are used to treat localized 
tumors, chemotherapy is used to control manifestations of systemic disease. For 
metastatic disease, chemo- and/or radiotherapy are used to help with problems 
associated with metastasis, whereas surgery at this unfortunate stage is used for 
palliation.  
1.5 Outcome 
The prognosis for patients with STS is predicted using nomograms established on 
tumor grade, tumor size, depth of the tumor, diagnosis, and age of the patient (16). 
Local recurrence is associated with tumor grade, margins (from surgical resection), 
and/or the use of radiation (14). Low grade STS have a chance of relapse beyond the 
5 year diagnosis; where High grade STS usually occur within the first 5 years upon 
diagnosis (14).  
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More than 50% of STS patients that develop distant metastasis regrettably succumb to 
the disease. Patients diagnosed with metastases have a median survival of about 12 
months from diagnosis (17, 18). 
One of the more dismally aggressive complex karyotypic STS is malignant peripheral 
nerve sheath tumors (MPNST).  
 
 
 
 
 
 
 
 
 
 
 
 
  
7 
 
Figure 3. Natural history of MPNST 
development. In the natural history of this 
disease, a child is born with heterozygous 
loss of NF1. As they grow, there is a loss 
of heterozygocity in Schwann cells leading 
to formation of neurofibromas, which in 
most cases are superficial or dermal. 
About 30-40% will develop deep plexiform 
neurofibromas. 8-13% of these plexiform 
neurofibromas acquire the loss of other 
genes, such as p53 and undergo malignant 
transformation to become an MPNST. 
  
 
Section 2: Malignant peripheral nerve sheath tumors (MPNSTs); an aggressive subset 
of genetically complex STS 
 2.1 Epidemiology 
MPNST make up about 3-10% of STS (19-21). More than 50% of patients that present 
with MPNST develop the disease within the background of an inherited disease known 
neurofibromatosis type I (NF1); the latter portion of MPNST patients develop the 
disease sporadically (22). The molecular hallmark of neurofibromatosis is the loss of 
the tumor suppressor neurofibromin, 
known for its role as a regulator of Ras 
(23-25). The incidence rate of 
developing MPNST among NF1 
patients occurs at 8 – 12% (22). Among 
NF1 patients, loss of heterozygocity of 
the NF1 gene occurs resulting in the 
development of benign superficial 
neurofibromas. Thirty to forty percent of 
the neurofibromas that develop grow 
deep (plexiform) within the NF1 patient 
and have an 8 – 13% lifetime risk of 
undergoing malignant transformation to 
become MPNST (25) (Fig. 3). 
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Figure 4. Diagnosis of MPNST . PET scan and 
gross cross-section of MPNST. (courtesy of Dr. 
Keila E. Torres, MD Anderson Cancer Center, 
Houston, TX) 
Neurofibromin loss alone does not translate to the malignant transformation, as other 
molecular derangements must occur to induce malignant transformation (25).  
 
2.2 Diagnosis and Treatment 
Upon diagnosis of MPNST, patients undergo a physical examination with a thorough 
observation of their patient history. Prior to acquiring a biopsy of the potential tumor, a 
radiological image of the patient is obtained. A common imaging modality for MPNST 
is with the use of magnetic resonance imaging (MRI), which may differentiate 
neurogenic tumors from non-neurogenic tumors of the soft tissues. Despite the 
imperative diagnostic role of MRI, this method lacks the ability to distinguish benign 
from malignant tumors, thus 
mandating the use of microscopic 
analysis of the tissue (Fig. 4). The 
criteria required to confirm the 
diagnosis of MPNST is based on 
one of the following settings: the 
tumor developed in association 
with a peripheral nerve or a 
plexiform neurofibroma, with 
features that are histologically 
compatible with MPNST. The 
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tumor histologically resembles an MPNST which has developed in a NF1 patient, the 
tumor exhibits the definite histological characteristics of an MPNST (26, 27). 
Complete surgical resection remains the primary mode of localized therapy. The aim 
of this front line treatment modality is complete surgical resection of the tumor with 
negative wide margins. Similar to its overall role in STS, systemic control of the 
disease by chemotherapy endures as a controversial therapy for MPNST (28-30). 
 
2.3 Outcome  
Diagnosis of MPNST unfortunately translates into a dismal prognosis, where many of 
these patients have non-resectable disease upon presentation. Patients who are 
diagnosed with primary disease have a 10-year disease-specific survival at about 
30%; however, this 10-year disease-specific survival drops to 26% in those with 
recurrent MPNST (28, 31). Patients with advanced disease (non-resectable and/or 
metastatic) respond poorly to chemotherapeutic intervention. The 5-year survival rate 
for patients with advanced disease is unfavorably at 20-50% (25), and the 10-year 
disease-specific survival is less than 8% (28). 
Complex karyotypic sarcomas including MPNST have an array of molecular 
derangements, where targeting a single molecule among the vast derangements 
would not be a rational form of therapy. A therapeutic strategy to combat the 
heterogeneous nature of complex karyotypic STS would be ideal. Histone deacetylase 
  
10 
 
(HDAC) inhibition is one such strategy that has been shown to induce a multitude of 
anti-cancer effects.  
 
Section 3: HDACs and the role of broad spectrum and isoform-specific HDAC 
inhibitors in cancer 
HDACs are a family of enzymes that deacetylate lysines on the core histones inducing 
the condensation of chromatin. Histone acetyltransferases (HAT) are the counterpart 
to HDACs as they acetylate lysine residues inducing an uncoiled conformation of 
chromatin. The balance of HDAC and HAT activity plays a significant role in 
epigenetics. This acetylation/deacetylation of lysine tails on histones was the initial 
consensus of HDACs and HATs (hence their name), however, various non-histone 
proteins, such as p53, β-catenin, Rb, NFκB, and E2F family members among various 
other protein substrates, were also discovered to be acetylated/deacetylated.  
Currently, eleven HDAC isoforms have been identified, including seven sirtuin 
isoforms (Nicotinamide adenine dinucleotide (NAD)+-dependent enzymes with 
deacetylase activity) in mammals (32, 33). HDACs have a catalytic domain that 
requires a metal ion (i.e. Zn, Fe) coordinates with oxygen of its carbonyl group to 
activate a water molecule with the support of histidine-aspartic acid for a nucleophilic 
attack resulting in the acetyl group to be removed from the target protein lysine 
residue. These isoforms (herein, only discussing HDAC isoforms), are organized into 
four classes based on sequence identity and domain organization (34, Fig. 5). Class I 
HDACs were initially believed to remain exclusively in the nucleus. However, HDAC3 
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Figure 5. Schematic depiction of HDAC isoforms and their sub-cellular localization. Bars 
depict the length of each isoform. Amino acid (aa) length is depicted on the right of each 
bar. Grey depicts the metal ion-dependent catalytic domain. 
Black depicts the nuclear localization sequence (NLS). N = N-terminus, C = C-terminus. 
Left column represents the sub-cellular localization of each isoform. 
  
 
and HDAC8 have been shown to be expressed in the nucleus and cytoplasm. Similar 
to HDAC3 and HDAC8, Class IIa and Class IIb HDACs have been shown to occur in 
both the nuclear and cytoplasmic compartments of various cells. HDAC6 and HDAC10 
have both been shown to play a cytoplasmic role more so than a nuclear role. Class IV 
solely consists of HDAC11 which share similarities to Class I and II HDACs.  
Mechanistically, HDACis work by chelating to the metal ion in the active site of 
individual HDAC isoforms inhibiting its deacetylation ability (35).  
The first experiments with compounds shown to inhibit HDACs were conducted in 
murine erythroleukemia cells (MELC) by various groups. Differentiation of the MELC 
cells occurred when treated with DMSO (36), TSA (37) or hexamethylene 
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bisacetamide (HMBA) (38). Trichostatin a (TSA) is a natural, hydroxamate-based 
compound, which was first discovered to induce hyperacetylation of histones by 
inhibiting HDAC isoforms (37). From these observations, compounds that share 
structural similarity to DMSO were created (38, 39). 
Suberoylanilide hydroxamic acid (SAHA), similar in structure to TSA, is one of the 
early, synthetically available HDACis shown to hyperacetylate histones, induce 
differentiation and inhibit proliferation in cancer cells at nanomolar ranges (38). Since 
these initial evaluations, several other natural HDACi compounds have been 
discovered along with the development of various synthetic HDACis of different 
chemical backgrounds. Due to its efficacy in transformed cells, SAHA 
(Vorinostat/Zolinza) was the first HDACi approved by the FDA (Food and Drug 
Administration) for the clinical use against cutaneous T cell lymphoma (CTCL) (40, 
41).  
Since these promising effects, the monotherapeutic efficacies of HDACis are being 
evaluated in preclinical in vitro and in vivo models in a variety of malignancies of 
different histologies. Many preclinical studies have lead way to the use of a variety of 
HDACis in clinical trials to evaluate the efficacy and toxicity of the drugs. Clinically, 
HDACis alone or in combination with another anti-cancer therapy (chemotherapy, 
radiotherapy) have generated promising anti-tumor activity. Currently, there are 
around 50 clinical trials evaluating the monotherapeutic efficacy of a variety of HDACis 
in cancers of various histology and more than 100 clinical trials evaluating the efficacy 
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of HDACis combined with various chemotherapeutic compounds 
(http://www.clinicaltrials.gov/, http://www.cancer.gov/clinicaltrials). 
The study of the efficacy of HDACis in sarcoma is limited. One of the earliest studies 
of HDACis in sarcoma occurred in 2002 where MS-275 was shown to have marked 
anti-cancer activity in pediatric osteosarcoma, malignant rhabdoid tumors, Ewing's 
sarcoma, and undifferentiated sarcoma (42). HDACis have also been shown to have 
superior efficacy in simple karyotypic soft tissue sarcomas including, synovial sarcoma 
(43-46), GIST (47), rhabdomyosarcoma (48-51) and complex karyotypic sarcomas 
such as fibrosarcoma (50, 52-54), leiomyosarcoma (50, 55), and MPNST (56, 57). 
Most of the HDACis currently used are broad-spectrum/pan inhibitors and target many 
HDAC isoforms with a high affinity to Class I HDACs, namely HDAC1, 2, 3. Due to the 
broad spectrum inhibition of these compounds, not much is known regarding the 
individual contribution of each HDAC isoform toward various malignancies. Inhibiting a 
multitude of HDACs has side effects where isoforms important for the tumorigenic 
nature are inhibited while redundant HDAC isoforms are also blocked resulting in 
undesirable effects on normal physiology. Park et al. (58) showed that by specifically 
inhibiting (via siRNA KD) HDAC1, 6, and 8 but not HDAC4 decreased matrix 
metalloproteinase 9 (MMP9) expression and the invasive capacity of breast cancer 
cells. This observation further illustrates the importance of individual HDACs and their 
contribution toward certain malignancies; owing toward the development of inhibitors 
for individual HDAC isoforms. 
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Recently, the development of HDAC8-specific inhibitors has paved a way to 
understanding the contribution of certain isoforms individually. Currently, specific 
inhibitors for HDAC6 (e.g. tubacin, tubastatin a) and HDAC8 are the only two isoform 
specific compounds, where the development of specific inhibitors for isoforms are 
underway. HDAC8’s structural uniqueness (59) from other class I HDAC isoforms has 
resulted in its isolation and subsequent crystallography structure, allowing for the 
development of specific inhibitors. 
The HDAC8 gene, located on the Xq13 chromosome, encodes a 377 amino acid long 
protein. Where classical class I HDACs are phosphorylated by casein kinase proteins, 
HDAC8 is phosphorylated at serine 39 by cyclic AMP-dependent protein kinase A 
(PKA) (60). Similar to other class I HDAC isoforms, HDAC8 possesses a nuclear 
localization sequence (NLS) in its catalytic domain. Unlike the ubiquitous distribution 
and expression of the other class I HDACs, HDAC8 has varying distribution among 
human tissues. HDAC8 has been shown to be at a higher expression in the brain and 
pancreas compared to HDAC1 and HDAC3, but at a lower expression level in other 
organs (i.e. heart, placenta, kidney, liver) compared to other class I HDACs (61, 62). 
Similar to other class I HDACs, HDAC8 expression is elevated in cancers of various 
histologies (61, 62). 
To date, little is known about the role of HDAC8 in normal physiology and cancer. Its 
role in the hyperacetylation of histones remains controversial where HDAC8 has been 
shown to deacetylate histones 3 and histone 4 in certain cells types, but not in others 
(63, 64). Among the few deacetylation targets, HDAC8-mediated deacetylation of 
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estrogen-related receptor alpha (ERRα) enhanced its DNA binding affinity, thus 
enacting its role in transcriptional regulation of various processes (65). Non-
deacetylation roles of HDAC8 have been identified. Phosphorylated-HDAC8 was 
shown to interact with human ever shorter telomeres 1B (hEST1B) by recruit Hsp70 to 
a complex that inhibits C-terminal heat shock protein interacting protein (CHIP), an E3 
ubiquitin ligase. This pHDAC8-mediated protection of hEST1B was independent of its 
acetylation state. Recent studies have shown that cytoplasmic HDAC8 interacts with 
smooth muscle alpha-actin (α-SMA) in muscle cells undergoing differentiation (66). 
Cytoplasmic HDAC8 has also been shown to have a diagnostic role in uterine 
mesenchymal tumors (67).  
Recently, three compounds with high affinities toward HDAC8 have been developed 
and are in current cancer-related studies: compound 2/HDAC inhibitor XIX 
(commercially available), PCI-34051, PCI-48012. 
HDAC8-specific inhibitor PCI-34051 (PCI3) is a potent inhibitor with a 4,200-fold 
selectivity over other HDAC isoforms. This compound was shown to induce apoptosis 
in T-cell lymphoma and leukemia cells lines, but not in cells derived from other B-cell 
or solid tumor cells lines (i.e. lung, colon, cervix, glioma, colon, breast ovarian). 
However, distinct from pan-HDACis, PCI3 did not induce the hyperacetylation of 
histones or tubulin in the cell lines tested (68). 
In neuroblastoma, HDAC8 expression was shown to correlate with an unfavorable 
outcome (69). Compound 2, a linkerless hydroxamate HDAC inhibitor with high 
specificity to HDAC8 was recently created (70), and tested on neuroblastoma cell 
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lines. Knockdown of HDAC8 as well as with the use of compound 2 induced the 
differentiation of neuroblastoma cell lines by stimulating the outgrowth neuritic-like 
structures. Inhibition of HDAC8 either by knockdown or by compound 2 abrogated 
neuroblastoma cell line proliferation, but did not induce apoptosis. HDAC8 inhibition-
induced expression of p21Waf1/Cip1 and NTRK1/TrkA was associated with the 
neuroblastoma cell line growth inhibition (69, 71). Interestingly, both neuroblastoma 
and MPNST derive from neural crest cell origins, suggesting a potential role for 
HDAC8 in the progression of these malignancies.  
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Chapter II: Hypothesis 
 
HDAC inhibition is a potentially novel therapy for the treatment of genetically complex 
STS. 
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Chapter III: Aims 
 
Aim 1: To preclinically determine the potential relevance of HDAC inhibition as a 
therapeutic modality for the treatment of genetically complex STS.  
1.1: Determine the effect pan-HDACi as a single agent 
1.2: Evaluate the role of pan-HDACi in combination with chemotherapy  
 
Aim 2: To test the efficacy of pan-HDACi for the treatment of MPNST 
2.1 Determine the efficacy of pan-HDACi in vitro and in vivo 
2.2 Identify the mechanisms of sensitivity and resistance to HDACi 
 
Aim 3: To assess the impact of HDAC8 inhibition on MPNST growth and pro-
tumorigenic phenotype 
3.1 Determine the effect of HDAC8 inhibition in vitro 
3.2 Ascertain the effect of HDAC8 inhibition in vivo 
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Chapter IV: Significance 
 
There is a critical need for novel therapeutic strategies to improve the dismal outcome 
of patients suffering from high grade STS and aggressive subtypes such as MPNST. 
In this pre-clinical study we show the promising efficacy of pan- and isoform-specific 
HDAC inhibition in a panel of genetically complex STS, namely MPNST. This report 
also gives insight into the molecular contributors influencing therapeutic resistance that 
can be circumvented by rational combination therapies. Initial findings from this study 
have been factorial in the launch of clinical trials evaluating the effect of pan-HDAC 
inhibition combined with chemotherapy for patients with high grade sarcomas. This 
report emphasizes the importance of these preclinical models for the utility of HDAC 
inhibition in sarcoma, a malignancy with limited therapeutic avenues. 
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Chapter V: Materials and Methods: 
 
Cell lines  
Human HT1080 (fibrosarcoma), RD (rhabdomyosarcoma), and SKLMS1 
(leiomyosarcoma) STS cells were obtained from the American Type Culture 
Collection. Primary normal human fibroblast (NHF) cultures were acquired from 
Promocell GmbH. MPNST cell lines utilized in these studies included the NF1-
associated: ST88 (provided by Dr Jonathan Fletcher, Brigham and Women’s Hospital, 
Boston, MA), T265 (provided by Dr George De Vries, Hines VA Hospital, Hines, IL), 
S462 (provided by Dr Brian Rubin, Cleveland Clinic, Cleveland, OH) and the 
MPNST642 isolated in our laboratory and the sporadic MPNST cell lines: STS26T 
(provided by Dr Steven Porcelli, Albert Einstein College of Medicine, Bronx, NY) and 
MPNST724 (provided by Dr Jonathan Fletcher) and were propagated and maintained 
as previously described (72). Murine-derived MPNST cell lines, NF1-TG-05 and -09 
were established in our laboratory and MPNST6IEP and MPNST6IEP4 were provided 
by Dr. Luis Parada (The University of Texas Southwestern Medical Center, Dallas TX). 
Primary human adult Schwann cell (NSC) cultures, used as controls for MPNST 
experiments were established from human cauda equina nerves were provided by Dr 
Patrick Wood (Miami Project, University of Miami, Miami, FL) and maintained as 
previously described (73). ST88, STS26T and MPNST724 cells were stably 
transfected to express GFP-LC3; overexpressing cells were FACS-sorted on the basis 
of green fluorescent protein (GFP) expression. Cells were cultured in DMEM 
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supplemented with 10% FBS (Life Technologies). DNA fingerprinting (short tandem 
repeat) was conducted for all cell lines less than 6 months prior to the conduct of the 
studies, confirming that no cross-contamination has occurred.  
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Antibodies  
mAb Name Company Application Ref 
Rad51 Santa Cruz WB 50 
Ac.H3 Millipore WB 50 
Ac.H4 Millipore WB 50 
Ac.tubulin Sigma WB 50 
β-actin Santa Cruz WB 50 
CD31 BD Biosciences IHC 50 
PCNA Dako Cytomation IHC 50 
E2F1 Santa Cruz ChIP 50 
E2F4 Santa Cruz ChIP 50 
RNA polymerase II Covance ChIP 50 
IgG Santa Cruz ChIP 50 
CTGF Santa Cruz WB 50 
CHK1 Cell signaling WB 50 
Mouse IgG Santa Cruz ChIP 50 
Rabbit IgG Santa Cruz ChIP 50 
LC3B Cell Signaling WB 
56 
GFP Santa Cruz WB 
56 
Beclin 1 Santa Cruz WB 56 
p53 Santa Cruz WB 56 
Ki67 MIB-1 IHC 56 
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IRGM Abcam WB 56 
PARP Abcam WB 56 
Caspase 3 Cell signaling WB 56 
NF1 Santa Cruz WB 56 
Table 1. Antibodies 
Antibodies were used for WB, ChIP, and IHC. Secondary antibodies included 
horseradish peroxidase–conjugated (Universal kit HRP; Biocare Medical) and 
fluorescent secondary antibodies (anti-rabbit Alexa488 and anti-mouse Alexa 594; 
Jackson Immuno Research). Other reagents included CytoQ FC Receptor block 
(Innovex Bioscience), Hoechst 33342 (Polysciences), and propyl gallate (ACROS 
Organics). 
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Drugs/compounds  
Compound Class Specificity 
PCI-24781 (PCI2) Hydroxamate Broad spectrum 
SAHA Hydroxamate Broad spectrum 
MS-275 Benzamide Class I 
PCI-34051 (PCI3) Hydroxamate HDAC8 
PCI-48012 (PCI4) Hydroxamate HDAC8 
Table 2. HDAC inhibitors used in this study were reconstituted in DMSO for in vitro 
studies. For in vivo use, PCI2 was dissolved in 50mM Sodium lactate, pH 4.2; PCI4 
was dissolved in 0.5% methylcellulose. 
Chemotherapeutic agents used in this study: Doxorubicin (Ben Venue Lab) and 
cisplatinum (Sicor) were obtained from the MD Anderson Cancer Center Pharmacy. 
Autophagy inhibitors: Bafilomycin A1 (Sigma; B1793) was reconstituted in DMSO and 
was only used for in vitro studies; Chloroquine (Sigma; C6628) was reconstituted in 
sterile deionized water and used for in vitro and in vivo studies.  
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Kits 
Kit Company Ref.  
CellTiter96 
Aqueous Non-Radioactive Cell Proliferation 
Assay kit Promega 50, 56 
Annevin V BD Biosciences 50, 56 
cDNA 1st strand synthesis Roche 50, 56 
Qiagen RNeasy® Mini Kit Qiagen 50 
TUNEL Promega 50, 56 
ChIP Upstate 50 
Stratagene Quick Change mutagenesis kit Stratagene 50 
Ras activity assay Cell Biolabs 56 
Autophagy RT2 Profiler PCR Array SA Biosciences 56 
 Table 3. Kits used in these studies were utilized per the manufacturer's instructions. 
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Cell culture based assays 
Western Blot 
Western blot analysis was performed by standard methods. Briefly, 25 - 50μg of 
proteins extracted from cultured cells were separated by SDS-PAGE and transferred 
onto nitrocellulose membranes. Membranes were blocked and blotted with relevant 
antibodies. HRP-conjugated secondary antibodies were detected by enhanced 
chemiluminescence (Amersham Biosciences, Plc.). 
 
Reverse transcriptase PCR (RTPCR) and Real time PCR (qRTPCR) 
These experiments were conducted as we have previously described (74). Primers 
used are depicted in the table below: 
Gene Forward primer Reverse primer 
*Rad51  TGGCCCACAACCCATTTCAC TCAATGTACATGGCCTTTCCTTCAC 
GAPDH  GAGCCACATCGCTCAGAC CTTCTCATGGTTCACACCC 
Rad51  GAGGTGAAGGAAAGGCCATGT GGGTCTGGTGGTCTGTGTTGA 
p21  GGAAGACCATGTGGACCTGT AATCTGTCATGCTGGTCTGC 
Actin  CAGCCATGTACGTTGCTATCCAGG AGGTCCAGACGCAGGATGGCATG 
IRGM  CCCTTCGAAACACAGGACAT AGTTCTCCAGGGTTGTGGTG 
CXCR4  GGTGGTCTATGTTGGCGTCT TGGAGTGTGACAGCTTGGAG 
TMEM74  TGACCAGGCAGATACAGCAG GTGGAGAAGTCCTGGTGGAA 
NFkB1  CCTGGATGACTCTTGGGAAA TCAGCCAGCTGTTTCATGTC 
ATG5  TGGGGTGGATATAGGGCATA  GACCTGGAGCCAATGAAAAA 
ATG7  ACCCAGAAGAAGCTGAACGA  CTCATTTGCTGCTTGTTCCA 
Table 4. Primer sequences used in these experiments. PCR primers for both assays 
were designed using primer 3 software. Total RNA was isolated from cultured 
STS/MPNST cells using TRIzol reagent (Invitrogen) per manufacturer's instructions. 
  
27 
 
Total RNA (1μg) was reverse transcribed using SuperScript III reverse transcriptase 
(Invitrogen) and 2μL of the product were used as templates. The PCR reaction mixture 
contained 2× PCR Master Mix (Promega), 0.2μM of primers (each 0.5μM), and 2μL 
cDNA. *Rad51 primers for RT-PCR. All other primers were designed for qRT-PCR. 
 
Tumor growth assays 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
Cell growth assays used CellTiter96 Aqueous Non-Radioactive Cell Proliferation 
Assay kit (Promega) per the manufacturer's instructions. Growth rates were analyzed 
48 - 96 h after HDACi (pan-HDACis: PCI-24781/SAHA/MS-275; HDAC8is: PCI-34051, 
PCI-48012) treatment and with doxorubicin or cisplatinum alone or combined with 
HDACi; several administration sequences were evaluated: 24 h pretreatment with 
PCI2 followed by the addition of chemotherapy for 24 h and conversely, pretreatment 
with chemotherapy followed by PCI2 as well as treatment with both compounds 
concomitantly for 24 h. Absorbance was measured at 490 nm wavelength; treated cell 
absorbance values are presented as a percentage of untreated cell absorbance.  
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Clonogenic assay  
STS and MPNST cells were plated at 100-200 cells per well in 6-well culture plates. 24 
h after plating, the cells were treated with DMSO (control) and varying concentrations 
of HDACi (pan-HDACis: PCI-24781/SAHA/MS-275; HDAC8is: PCI-34051, PCI-48012) 
for 24 h or continuous treatment. In combination studies, MPNST cells were first 
treated with an autophagy inhibitor (BFA/CQ) for 24 h then combined with HDACi for 
an additional 24 h. After combination therapy the drugs were removed and fresh media 
was added to the test wells; cells remained in fresh media (changed every 48 h) for 10 
days. After 10 days, the cells were stained with a 6% glutaraldehyde, 0.5% crystal 
violet solution for 30 min. Staining solution was decanted from each well and cells 
washed with deionized H2O. Individual colonies retaining staining solution were 
counted.  
 
Cell cycle FACS analysis  
Cells were treated with pan-HDACis (PCI-24781/SAHA) or HDAC8is (PCI-34051/PCI-
48012) for varying periods. Propidium iodide/fluorescence-activated cell sorting 
(FACS) analysis was conducted as described (75). 
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Apoptosis assays 
Apoptosis was measured using the Apoptosis Detection kit I (BD Biosciences, San 
Jose, CA) per manufacturer’s recommendations. As a standard, 1x106/mL of cells per 
treatment condition (time and dose as indicated) were fixed and stained with 5μL 
Annexin V–FITC (BD PharMingen, San Diego, CA) and 5μL propidium iodide (Sigma, 
St Louis, MO). Flow cytometric analysis was performed for 1x104 cells and analyzed 
by FACScan (Becton Dickinson, Franklin Lakes, NJ) using a single laser emitting 
excitation light at 488 nm. Data were analyzed by CellQuest software (Becton Dickson, 
Franklin Lakes, NJ). To confirm annexin V-FITC FACS results, WBs were conducted 
on samples similarly used for annexin V-FITC FACS. Westerns were blotted for 
apoptotic markers: cleaved caspase 3 and/or cleaved PARP.  
 
Transfection procedures 
 siRNAs (pools targeting: beclin, ATG5, ATG7, IRGM, p53, and control non-targeting 
constructs, Thermo Scientific, Dharmacon) were introduced into cells using X-
tremeGENE (Roche) per manufacturer’s instructions. Briefly, 2x105 cells were plated in 
each well of a six-well plate and incubated overnight. A mixture of siRNA (20nM) and 
X-tremeGENE diluted in Dulbecco's modified Eagle medium (DMEM) was added for 
24 h, followed by incubation in regular medium. Cells were harvested at indicated time 
points for specific experiments. 
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p53 transfection 
Adp53 and AdLacZ adenoviruses were produced and titered by the Vector Core 
Laboratory at M.D. Anderson Cancer Center. Transfection procedures were conducted 
as we have previously described (76). 
 
Autophagy assays  
Transmission electron microscopy (TEM)  
MPNST cells were grown in 6-well culture plates and treated with PCI2 (1μM) or 
DMSO alone for 24, 48, or 72 h and then fixed for one hour with a solution containing 
3%  glutaraldehyde plus 2% paraformaldehyde in 0.1M cacodylate buffer (pH 7.3). 
After fixation, the samples were post-fixed in 1% OsO4 in the same buffer for 30min 
then stained with 1% uranyl acetate. Representative areas were chosen for ultrathin 
sectioning and electron microscopic viewing (JEM 1010 transmission electron 
microscope; JEOL, Peabody, MA), as previously described (77). Digital images were 
also obtained (AMT imaging system; Advanced Microscopy Techniques Corp., 
Danvers, MA). Three replicates were performed for each experiment.  
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Acridine orange staining and FACS analysis 
Autophagy was evaluated in MPNST cell lines by the staining of acidic vesicular 
organelles as previously described (78, 79). Briefly, MPNST cell lines were treated 
with pan-HDACis or DMSO (control). 48 h later, cells were stained with acridine 
orange (1μg/mL; Sigma-Aldrich) for 15 min; samples were examined and images were 
taken using a fluorescence microscope. For further quantification, cells were treated 
and stained as above, trypsinized, and analyzed via flow cytometry. Green (510-
530nm) and red (>650nm) fluorescence emission from 2x104 cells illuminated with 
blue (488nm) excitation light was measured using FACS Calibur (Becton Dickinson) 
using CellQuest software.  
 
LC3 conversion 
Conversion of soluble LC3-I to lipid bound LC3-II is associated with the formation of 
autophagosomes. Cleavage of LC3 at the carboxy terminus immediately following 
synthesis yields the cytosolic LC3-I form. During autophagy, LC3-I is converted to 
LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows 
LC3 to become associated with autophagic vesicles. The presence of LC3 in 
autophagosomes and the conversion of LC3 to the lower migrating form LC3-II have 
been used as indicators of autophagy. WB for LC3 demonstrating enhanced 
expression of LC3B-II (normalized to actin) is an indicator of increased number of 
autophagosomes. The inhibitors chloroquine and bafilomycin block the last stages of 
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productive autophagy thus will result in autophagosome accumulation; WB for LC3B-II 
in the presence of these inhibitors is expected to show increased LC3B-II levels 
(normalized to actin). Combining chloroquine or bafilomycin with compounds that 
enhance productive autophagy is expected to show further increase in LC3B-II 
expression. 
 
GFP-LC3 puncta 
MPNST cells were stably transfected to express GFP-LC3 (STS26T, MPNST724, 
ST88); overexpressing cells were FACS-sorted on the basis of green fluorescent 
protein (GFP). The presence and images of GFP-LC3 puncta was observed using 
fluorescent microscopy. 
 
GFP cleavage assay 
When GFP-LC3 is delivered to a lysosome the LC3 part of the chimera is sensitive to 
degradation, whereas the GFP protein is relatively resistant to hydrolysis. Therefore, 
the appearance of free GFP on WB (blotted for GFP) can be used to monitor lysis of 
the inner autophagosome membrane and breakdown of the cargo, indicative of 
productive autophagy (79). Lysate preparation and western blotting of GFP-LC3 cells 
samples were conducted as mentioned above.  
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 Therapeutic animal experiments 
 
Effect of monotherapy on local xenograft growth  
All animal procedures and care were approved by the MD Anderson Cancer Center 
Institutional Animal Care and Usage Committee. Animals received humane care as 
per the Animal Welfare Act and the NIH “Guide for the Care and Use of Laboratory 
Animals.” Animal models were utilized as previously described (78). Trypan blue 
staining confirmed viable cells (SKLMS1 or HT1080 cells 1x106/0.1 mL HBSS/mouse; 
STS26T, MPNST724, or MPNST642 cells 1-2x106/0.1 mL HBSS/mouse; 
MPNST6IEP4 cells 1x106/0.1 mL HBSS/mouse) were injected into the flank (SKLMS1 
i.m., HT1080, STS26T, MPNST724, MPNST642, MPNST6IEPVI s.c.) of 6-wk-old 
female SCID mice (MPNST cells were injected into hairless SCID mice), growth was 
measured twice weekly. When average tumor volumes reached 100 mm3, the mice 
were assigned to treatment groups (7-8 mice/group). STS/MPNST cells were allocated 
into 2 treatment arms: Vehicle; HDACi/HDAC8i (PCI2 [25-50mg/kg BID 5X d/wk, i.p.]; 
PCI4 [20mg/kg BID 5X d/wk, i.p.]). PCI2/PCI4 dose and treatment schedules were 
determined per company recommendations. The mice were followed for tumor size 
and body weight and sacrificed when control group tumors reached 1.5 cm average 
largest dimension. Tumors were resected, weighed, and frozen or fixed in formalin and 
paraffin-embedded for immunohistochemical studies.   
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Effect of monotherapy on autophagy  
MPNST724 and STS26T GFP-LC3 cells were injected into the flank of hairless SCID 
mice s.c. When palpable tumors reached average diameter ~10mm, STS26T GFP-
LC3 xenografts were treated with either vehicle or PCI2 (25mg/kg), and mice were 
euthanized 2, 4, and 6 h after treatment. MPNST724 GFP-LC3 xenografts (when 
average diameter ~10mm) were allocated into four treatment arms: Vehicle, PCI2 
(25mg/kg), chloroquine (50mg/kg), PCI2 + CQ. Mice were treated with CQ a day prior 
to combining with PCI2. Mice from these groups were euthanized after 24 h treatment 
(groups receiving CQ were treated with this compound for 48 h). Resected tumors 
were processed for lysate and analyzed on WB. 
 
Effect of monotherapy on metastatic growth  
HT1080GL (for studies in Lopez et al. 2009) or STS26TGL (for studies in Lopez et al. 
2010) cells (stably expressing green fluorescent protein/Luciferase; GL) were tail vein 
injected, resulting in experimental lung metastases that could be followed by 
bioluminescence. A similar experimental design used for local growth experiments 
were used for lung metastasis experiments. Treatment was initiated when 
bioluminescence showed established lung metastases. The mice were followed and 
euthanized when bioluminescence suggested control group had significant pulmonary 
tumor load. Lungs were resected, weighed, and fixed in formalin for the creation of 
paraffin blocks.  
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Combined HDACis with conventional chemotherapy  
For local growth studies, SKLMS1 or HT1080 cells (1x106/0.1 mL HBSS/mouse) were 
injected s.c. into the flank of 6-wk-old female SCID mice; growth was measured twice 
weekly. When average tumor volumes reached 100mm3, the mice were assigned to 
treatment groups (7-8 mice/group). STS cells were allocated into 4 treatment arms: 1) 
vehicle; 2) doxorubicin/cisplatinum (1.2mg/kg/biweekly and 2 mg/kg/biweekly, 
respectively, i.p.); 3) PCI2 (50mg/kg BID 5X d/wk, i.p.); and 4) PCI2 + chemotherapy 
(PCI2 initiated 24 h before chemotherapy in all cases). PCI2 dose and treatment 
schedules were determined per company recommendations. The mice were followed 
for tumor size and body weight and sacrificed when control group tumors reached 1.5 
cm average largest dimension. Tumors were resected, weighed, and frozen or fixed in 
formalin and paraffin-embedded for immunohistochemical studies.   
For lung metastasis model, HT1080GL cells were used. Lung metastasis models were 
conducted as mentioned above. 
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Combined HDACi with autophagy blockade  
For experiments evaluating effect of treatment on local tumor growth trypan blue 
staining confirmed viable MPNST cells (MPNST642, MPNST724 and STS26T; 1-
2x106/0.1 mL HBSS/mouse) were used. Cell suspensions were injected 
subcutaneously into the flank of six week old female hairless SCID mice (n 
=10/treatment group) and growth was measured twice weekly; after establishment of 
palpable lesions (average diameter >5mm) mice were assigned to treatment groups as 
described below. An experimental lung metastasis MPNST model was used to 
evaluate metastases’ growth. STS26T cells (1x106/0.1 mL HBSS/mouse) were 
injected into the tail vein of female SCID mice. Ten days after injection (a time-point by 
which 95-100% of mice develop established lung metastases) mice were allocated to 
treatment groups as per below. Therapeutic regimens included a four armed study: 1) 
DMSO; 2) PCI2 (25mg/kg/d for five days/week); 3) chloroquine (50mg/kg/d for five 
days a week); and, 4) combination of PCI2 and chloroquine. In the latter studies, 
including a chloroquine arm, this drug was initiated a day prior to PCI2 treatment. Mice 
were followed for tumor size, well-being, and body weight and sacrificed when control 
group tumors reached an average of 1.5 cm in their largest dimension. Tumors were 
resected, weighed, and frozen or fixed in formalin and paraffin-embedded for 
immunohistochemical studies. For lung metastasis studies mice were followed for 
body weight and well-being and sacrificed after two weeks of treatment. Lungs were 
resected, evaluated macroscopically for tumor load and weighed. 
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Tissue based experiments 
 
 Immunohistochemistry (IHC) 
IHC and terminal deoxyribonucleotide transferase–mediated nick-end labeling 
(TUNEL) assays were conducted on paraffin and frozen sections, respectively. 
Conventional H&E staining was done (MD Anderson core facility) and examined by 
light microscopy. IHC was done using anti-Ki67 (1:500; DAKO Carpinteria, CA), anti-
PCNA (1:500; DAKO Carpinteria, CA), and anti-CD31 (1:50; PharMingen, San Diego, 
CA). Fluorometric TUNEL System (Promega; Madison, WI) was used to detect DNA 
fragmentation on frozen sections as per the manufacturer’s protocol.  
 
WB and RTPCR/qRTPCR (from in vivo tissues) 
For protein lysates; cells were washed twice with cold PBS. Whole cell lysate was 
added to the cells and the plate remained at 4°C for 20 min. The cells were then 
scraped using a cell scraper and the lysate was placed in a 1.5mL pre-chilled 
Eppendorf tube. The lysate was then placed on a rotator at 4°C for 20 min. The lysate 
was then centrifuged at 140,000 rpm at 4°C for 10 min. The supernatant was 
transferred to a fresh, 1.5mL pre-chilled Eppendorf tube and stored at -80°C until 
further use.  
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For mRNA-based experiments, cells were washed twice in cold PBS. TRIzol was 
added to the cells and the plate was placed on a rocker for 10 min at room 
temperature. After 10 min, samples were placed in a 1.5mL pre-chilled Eppendorf 
tube.  
 
High throughput experiments 
 
Autophagy qRT-PCR array 
Total RNA was isolated from MPNST724 and STS26T cells (PCI-24781 treated 
[0.5μM/24h] and untreated) using TRIzol. After DNase treatment, RNA was further 
cleaned up using Qiagen RNeasy® Mini Kit (Qiagen, Valencia, CA). cDNA was 
synthesized by RT2 First Strand kit SABiosciences, Frederick, MD) following 
manufacturer’s instructions. Gene expression profiling using the Autophagy RT2 
ProfilerTM PCR Array (SABiosciences, Frederick, MD) was conducted. This platform is 
designed to profile the expression of 84 key genes involved in autophagy (for a 
comprehensive list of included genes see www.sabiosciences.com). qRTPCR was 
conducted using Mastercycler Epgradients realplex (Eppendorf AG, Hamburg, 
Germany) based on array manufacturer’s instructions. Relative gene expression was 
determined using the ΔΔCT method. Data were further analyzed by PCR Array Data 
Analysis Web Portal (www.SABiosciences.com/pcrarraydataanalysis.php). All 
experiments were repeated twice. 
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Statistics 
 
Statistical analysis for tissue culture based experiments 
Cell culture-based assays (and Western blot analyses) were repeated at least three 
times; mean ± SD was calculated. Cell lines were examined separately. For outcomes 
that were measured at a single time point a two-sample t-test was used to assess 
differences; a linear mixed model was used to assess treatment effects and 
association between compounds. 
 
Statistical analysis for animal experiments 
For STS and MPNST-based in vivo experiments (50, 56) the average (AVG),standard 
deviation (STDV)/standard error mean (SEM), and range for all in vivo experiment 
group variables were calculated and recorded. Tumor weights (g) and lung weights (g) 
for each treatment group were measured for the following: 1st quartile, 3rd quartile, 
maximum, minimum, median. All tumor weight and lung weight data are depicted as 
box plots. The number of lung metastases for (56) are depicted as a dot plot. For 
outcomes that were measured at a single time point, 2-sample t-tests were used to 
assess the differences. Differences in xenograft growth (tumor/metastases) in vivo 
were assessed using a 2-tailed Student's t-test. IHC analysis (Ki67, TUNEL) were 
assessed using 2-tailed Student’s t-test. Significance was set at p ≤ 0.05.  
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Figure 6. Western blot analysis showing HDACi (PCI2 and SAHA) induced time- and 
dose-dependent increase in histone 3, histone 4, and tubulin acetylation in STS cells. 
This increase in acetylation is a marker for the HDAC inhibitory effect of these 
compounds. Modified from Figure 1, Lopez et al. Clin Cancer Res 2009;15:3472-3483. 
  
 
Chapter VI: Results 
 
Section 1: Aim 1: The potential effects of HDACis on genetically complex STS 
1.1 Effects as monotherapy 
The goal of this initial set of studies was to evaluate the effects of pan-HDAC inhibitors 
on the growth of genetically complex human STS cells in vitro. The hydroxamic acid-
based pan-HDACis used were PCI2 and suberoylanilide hydroxamic acid 
(SAHA/Vorinostat). To first confirm that these compounds truly inhibit HDAC activity in 
our cell lines and induce protein acetylation in situ. The expression of acetylated 
histone 3 and histone 4 and acetylated tubulin was via western blot. A time- and dose-
dependent increase in acetylated histones 3, 4 and tubulin was observed using both 
compounds in human STS cell lines of diverse histology and differential p53 status: 
Fibrosarcoma (HT1080, wild type p53), rhabdomyosarcoma (RD, mutated p53), and 
leiomyosarcoma (SKLMS1, mutated p53) (Fig. 6). 
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We next evaluated the effects of HDAC inhibition on STS cell growth in vitro. Both 
HDACis induced a dose-dependent decrease in cell growth after 48 h treatment, with 
all three cell lines showing more sensitivity to PCI2 compared to SAHA when assayed 
via MTS (Fig. 7A). No significant effect on the growth of normal human fibroblasts 
(NHF) was observed. Resistance of normal cells to the effects of HDACi has been 
previously reported (81), and our data repeated these findings. A marked effect on 
STS clonogenic capacity was noted with both compounds (Fig. 7B). These 
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Figure 7. A, MTS assays demonstrating the effect of HDAC inhibition (48 h) on STS cell 
growth. Although STS cell growth inhibition was seen with both agents, a more 
significant response to PCI2 was observed in cells tested. No effect was seen after 
treatment of normal human fibroblasts (NHF). B, HDACis abrogate STS cell colony 
formation capacity. Right panel, number of colonies counted in experiments repeated 
three times. Results represent the average of a minimum of three replications (± SD). 
Modified from Figure 1, Lopez et al. Clin Cancer Res 2009;15:3472-3483. 
  
 
later assays were conducted using a 24 h treatment, the compounds were removed 
and the cells were grown in normal media for 14 days.   
Together these data suggest that HDACis inhibit the growth of genetically complex 
STS cell lines regardless of histological subtype and differential p53 status, supporting 
additional investigation on the impact of HDACis on STS in vitro and in vivo. 
Next we aimed to determine whether HDACi-induced growth inhibition is secondary to 
abrogated cell cycle progression and/or cell death. First, to assess the effect of 
HDACis on the cell cycle, STS cell lines were treated with IC50 doses of both drugs for 
48 h and propidium iodide (PI) staining/FACS were conducted. Both drugs were found 
to induce G2/M cell cycle arrest, in the cell lines tested, independent of p53 mutational 
status (Fig. 8A). For example, PCI2 (0.5μM) treatment for 48 h, resulted in decreased 
proportion of S-phase cells from 42 ± 6.4% to 26 ± 9.1% and from 34 ± 5% to 17 ± 5%, 
in RD (p53 mut.) and HT1080 (p53 wt) cells, respectively. Whereas G2/M phase cells 
increased from 22 ± 1.7% to 64 ± 3.6% and from 30 ± 6.4% to 49 ± 5.7%, respectively 
(p < 0.05). Similarly, SAHA induced S-phase depletion and G2/M arrest in both cell 
lines. Cell cycle analyses also demonstrated an increase in the sub-G1 fraction in cell 
lines treated with either HDACi, indicative of fragmented DNA, suggesting HDACi-
induced cell death. To test whether increased sub-G1 fraction is the result of 
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Figure 8. A, PI staining/FACS analyses showing the effect of HDACis (PCI2 0.5 μM/48 
h, SAHA 2 μM/48 h) on STS cell cycle progression. A significant (p < 0.05) reduction in S 
phase cells and G2 arrest is seen. Additionally, an increase in sub G1 population is 
observed, suggesting cell death. B, PCI2 induced STS cell apoptosis in a time- and 
dose-dependent manner (Annexin V/PI staining FACS analyses). Modified from Figure 2, 
Lopez et al. Clin Cancer Res 2009;15:3472-3483. 
  
 
apoptosis, annexin V/PI staining FACS analyses were conducted. PCI2 induced 
marked apoptosis in a dose- and time-dependent manner (Fig. 8B). Although only 
minimal apoptosis was seen 24 h after exposure to PCI2, 74% ± 14 and 64% ± 25 
Annexin V positivity was observed in HT1080 and RD cells, respectively, after 96 h of 
PCI2 (0.5μM) treatment. In brief, HDAC inhibition abrogated STS growth by inducing 
G2/M cell cycle arrest and apoptosis in vitro.  
Prior to testing the effects of HDACis on STS growth in vitro we opted, as depicted in 
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Figure 9. Pretreatment of STS cells with PCI2 
(0.1μM/24h) sensitizes STS cells to chemotherapy. 
A superior effect was shown when combining PCI2 
and doxorubicin (0.5μM/24 h; p < 0.0001) or 
cisplatinum (1μM/24h; p < 0.05) as compared with 
each agent alone. When sequencing was reversed, 
i.e. pretreatment with chemotherapy (24 h) followed 
by the addition of PCI2 (24 h), or when the drugs 
were administered concomitantly for 24 h, no such 
superior effect was observed (data not shown). 
Modified from Figure 2, Lopez et al. Clin Cancer Res 
2009;15:3472-3483. 
  
 
the next section to identify HDACi-based therapeutic combinations that demonstrate 
superior anti-STS effects as compared to monotherapy. 
 
1.2 Combining HDACis with conventional chemotherapy 
Multiple lines of evidence suggest that combining HDACis with conventional 
chemotherapy and/or radiation, result in synergistic anti-cancer effects (82-84). We 
aimed to determine if these 
findings can be recapitulated 
in STS. To that end we 
examined the efficacy of low 
dose PCI2 (0.1M) in 
combination with low doses of 
two different chemotherapeutic 
drugs commonly used as a 
treatment for STS: the 
anthracycline drug doxorubicin 
(0.5µM) and the DNA cross-
linking drug, cisplatinum (1µM). 
Cells were pretreated with PCI2 
alone for 48 h, chemotherapy alone for 24 h, or by sequential combination of PCI2 and 
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chemotherapy (cells pretreated with PCI2 for 24 h, then chemotherapy was added for 
an additional 24 h). MTS assays were conducted at 48 h (Fig. 9). The combination of 
PCI2 (0.1μM) and doxorubicin (0.5μM) caused growth reductions of 77% ± 4.7, 81% ± 
3.1, and 65% ± 3.5 in HT1080, RD, and SKLMS1 cells, respectively. In contrast, low 
dose PCI2 alone resulted in 23% ± 3.2, 24% ± 5.6, and 12% ± 4.4 growth inhibition of 
HT1080, RD, and SKLMS1 cells, whereas low dose doxorubicin alone caused 6% ± 
9.5, 10% ± 4.5, and 9% ± 4.5 growth reduction, respectively. Statistical analysis 
showed a statistically significant, superior effect for combination compared with each 
compound alone (PCI2 plus doxorubicin p < 0.001; PCI2 plus cisplatinum, p < 0.05; 
Fig. 10). A similar pattern was seen when PCI2 was combined with cisplatinum. 
Interestingly, this effect was lost when drugs were administered together for 24 h or 
when cells were pretreated with chemotherapy for 24 h prior to PCI2 treatment (data 
not shown), suggesting that PCI2 possibly sensitizes STS cells to the effect of 
chemotherapy. 
Recognizing the anti-STS effects of HDACis as monotherapy and more so in 
combination with chemotherapy in vitro we next aimed to assess whether this impact 
can also be observed in vivo. Three human xenograft SCID mouse models were 
utilized: two local growth models, SKLMS1 growing intramuscular and HT1080 
growing subcutaneous, and an experimental lung metastasis model, using HT1080. 
Each of these models were used in a four-armed study to evaluate the efficacy of PCI2 
alone, doxorubicin or cisplatinum alone, and the combination of PCI2 with either 
chemotherapy. Of note, PCI2 was administered first and chemotherapy was 
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administered on day 2. For local growth models, the therapy commenced when tumors 
were at ~100mm3. Bioluminescence was used to identify the establishment of lung 
metastases for the experimental lung metastasis model; once the mice had a 
comparable establishment of bioluminescence in the chest cavity, the treatment was 
started. The mice were followed for tumor size and body weight and sacrificed when 
control group tumors reached 1.5 cm average largest dimension or when 
bioluminescence suggested control group had significant pulmonary tumor load. 
Effects of tumor growth were statistically assessed using a linear mixed model. To 
determine the impact of treatments on tumor weights at termination of study, a linear 
regression model was used.  
In the first experiment, SKLMS1 xenografts were used and the effects of PCI2, 
doxorubicin and their combination were evaluated (Fig. 10A). Treatment with low-dose 
doxorubicin alone or PCI2 alone did not significantly affect SKLMS1 xenograft growth 
(p = 0.06 and p = 0.015, respectively). Combining PCI2 with low dose doxorubicin 
resulted in significant growth inhibition compared to either drug alone (p < 0.0001) (Fig 
11A). Tumor volume at study termination was: control 1738mm3 ±334, doxorubicin 
1253.1mm3 ±281.5, PCI2 1182mm3 ±329, combination 460.3mm3 ±240. Similarly, 
PCI2 and more so PCI2 + doxorubicin resulted in significant reduction in tumor weights 
at study termination as compared to control and doxorubicin alone treatment groups (p 
= 0.026, < 0.0001, = 0.0023, = 0.047, respectively) (Fig 10B). Average group tumor 
weights at study termination were 1.62g ± 0.47 for control, 1.34g ± 0.43 for 
doxorubicin, 1.11g ± 0.26 for PCI2, and 0.64g ± 0.24 for combination. H&E staining of 
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Figure 10. Combining PCI2 (50mg/kg/d) with low-dose doxorubicin (1.2mg/kg/biweekly) results 
in significant reduction SKLMS1 xenograft growth in SCID mice. A, tumor growth curves 
showing a significant synergy between the two drugs (p < 0.0001). B, PCI2 alone effects on 
tumor weight were statistically significant (p = 0.026) compared with controls. Most importantly, 
the reduction in tumor weight due to combined PCI2/chemotherapy was very statistically 
significant compared with the other treatments (p < 0.0001, = 0.0023, and = 0.047 versus 
control, doxorubicin, and PCI2 groups, respectively). C, IHC analysis of xenograft specimens 
showing enhanced tumor necrosis in PCI2–treated tumors, and most significantly in 
combination therapy specimens (H&E), decreased tumor proliferation (PCNA) and increased 
apoptosis (TUNEL). No significant differences in CD31 counts were seen; however, a marked 
decrease in the number of large, patent blood vessels was discernible in the combination 
group. Modified from Figure 3, Lopez et al. Clin Cancer Res 2009;15:3472-3483. 
  
 
different treatment arm tumors revealed marked tumor necrosis in PCI2 and 
combination treatment groups (Fig 10C); viable tumor sections were 
immunohistochemically evaluated for the impact of different therapies on STS cell 
proliferation (PCNA) and apoptosis (TUNEL). Average PCNA and TUNEL-positive 
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staining nuclei revealed 88 ± 2 and 20 ± 2.4 for control, 85 ± 1.2 and 16 ± 1.4 for 
doxorubicin, 71 ± 2.3 and 19 ± 1.1 for PCI2, and 57 ± 4.6 and 61 ± 18.4 for 
combination, respectively. Together these data suggest that combination therapy had 
the strongest anti-proliferative and apoptosis-inducing effects (p < 0.05). Sections were 
also stained for CD31 to examine therapy effects on tumor-associated vasculature. No 
significant differences in CD31 counts were seen; however, markedly decreased 
numbers of large, patent blood vessels was discernible in the combination group (Fig 
10C). 
The second mice experiment evaluated the effects of PCI2, cisplatinum and their 
combination on the growth of established HT1080 xenografts (Fig. 11A). Cisplatinum 
and PCI2 when administered as single agents had only minimal effects on HT1080 
tumor growth. However, significant tumor growth delay was observed with combined 
therapy (p < 0.001 versus all other treatment groups; Fig. 11A). This was also 
reflected in a significantly reduced tumor volume at study termination for xenografts 
treated with therapeutic combination. Tumor volumes were: control 1437.1mm3 ±419, 
cisplatinum 1031.5mm3 ±574.8, PCI2 1078.7mm3 ±567.7, combination 254.8mm3 
±200 (p < 0.001 for combination compared to all other therapeutic arms). Average 
group tumor weights at study termination were 1.23g ± 0.15 for control, 1.01g ± 0.39 
for cisplatinum, 1.09g ± 0.54 for PCI2, and 0.36g ± 0.22 for combination (Fig 11B). 
Statistical analysis determined that combination therapy significantly reduced tumor 
weight as compared to control, cisplatinum, and PCI2 alone (p = 0.0003, = 0.0038, 
and = 0.0011, respectively). IHC results were similar to those for the SKLMS1-treated 
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Figure 11. Combining PCI2 (50mg/kg/d) with low-dose cisplatinum (2mg/kg/biweekly) results in 
significant reduction of HT1080 xenograft growth in nude mice. A, tumor growth curves showing 
a significant synergy between PCI2 and cisplatinum in vivo (p < 0.001). B, a highly statistical 
significant tumor weight reduction was observed with combined treatment compared with the 
other three groups (p = 0.0003, = 0.0038, and = 0.0011 versus control, cisplatinum, and PCI2 
groups, respectively). C, as observed in SKLMS1 xenografts, enhanced tumor necrosis in 
PCI2-treated tumors, and most significantly in combination therapy specimens was observed in 
HT1080 tumors (H&E). Decreased tumor proliferation (PCNA) and increased apoptosis 
(TUNEL) was also seen. No significant differences in CD31 counts were shown; however, a 
marked decrease in the number of large, patent blood vessels was discernible in the 
combination group. Modified from Figure 4, Lopez et al. Clin Cancer Res 2009;15:3472-3483. 
  
  
 
tumors described above, showing increased necrosis in PCI2 and combination groups 
(Fig. 11C). Decreased proliferation and enhanced apoptosis were most pronounced in 
the combination-treated group (average PCNA and TUNEL-positive staining nuclei 
were 83 ± 7.1 and 18 ± 0.3 for control, 62 ± 2.8 and 17 ± 2.5 for cisplatinum, 50 ± 2.8 
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and 21 ± 5.9 for PCI2, and 38 ± 14.1 and 33 ± 8.6 for combination, respectively; p < 
0.05). No significant difference in CD31 positivity was seen among groups, whereas a 
reduction in large blood vessels was observed in the combination group. 
Together, both these studies suggest that PCI2 alone while highly effective in vitro 
does not induce dramatic anti-growth effects in vivo using the dose and regiment 
selected. However, combining PCI2 with chemotherapy markedly improves ant-STS 
effects in vivo. 
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While previous studies focused on the effects of PCI2 ± chemotherapy on local growth 
it is even more important to evaluate whether this therapeutic regiment can impact the 
growth of STS metastasis which is the cause for STS patient death. A major limitation 
to being able to assess the effects of therapy on STS metastatic development and 
growth is the current lack of spontaneous STS metastasis models. To that end, for our 
studies, we utilized an experimental STS lung metastasis model where HT1080 cells 
are injected i.v. into mice tail vein. Lung metastases are commonly visible at ~2 weeks 
after injection. To be able to follow-up the development and growth of lung metastases 
in these mice, we utilized HT1080 cells stably transduced top express GFP/luciferase 
(GL) and metastasis volume was determined using bioluminescence (BLI). Mice were 
allocated into six treatment arms after pulmonary metastases were confirmed per BLI 
and treatment was initiated (Fig. 12). Drug combination sequencing was done similar 
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Figure 12. Combining PCI2 (50mg/kg/d) 
with low-dose cisplatinum 
(2mg/kg/biweekly) or doxorubicin 
(1.2mg/kg/biweekly) results in significant 
reduction of HT1080 pulmonary metastatic 
growth in nude mice. Nude mice injected 
with HT1080 cells (1x106/mouse) through 
tail vein were followed using 
bioluminescence. Treatment (as recorded) 
was initiated after bioluminescence 
suggested established lung metastases ~3 
weeks after cell injections. Sequential 
bioluminescence imaging of mice from 
each treatment arm show a substantial 
increase in luciferase readout in control, 
cisplatinum-, doxorubicin-, and PCI2-
treated groups; decreased readouts were 
noted in combination therapy groups. H&E 
staining demonstrated only limited lung 
metastatic deposits in combination-treated 
groups (microscopic metastasis are 
marked by arrow heads) as compared to 
large metastatic load in other treatment 
arms. Modified from Figure 4, Lopez et al. 
Clin Cancer Res 2009;15:3472-3483. 
to the previously mentioned therapeutic 
experiments. Experiment was terminated 
when BLI readout in control treated mice 
suggested an extensive metastatic load (~3 
weeks after therapy initiation). At this time 
point, as depicted in Fig. 12, readout 
demonstrated a markedly reduced 
pulmonary tumor load in mice treated with 
combination therapies as compared to 
vehicle, PCI2, or chemotherapy arms alone. 
Lung metastases load was also enhanced 
on H&E staining of the lungs. Vehicle and 
monotherapy-treated lungs demonstrated 
massive tumor load replacing almost 
entirely the lung parenchyma, whereas 
combination treated lungs demonstrated no 
or only microscopic results.  These 
differences were also notable per lung 
weights (treated lung metastases weights 
were calculated by deducting the estimated 
average normal mouse lung weight from 
actual lung weight at study termination), where combination therapy-treated lungs 
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were significantly smaller in weight compared to vehicle and monotherapy. Average 
lung metastases weight per group was 0.55g ± 0.14 for control, 0.62g ± 0.26 for 
cisplatinum, 0.48g ± 0.33 for doxorubicin, 0.33g ± 0.20 for PCI2 group, 0.15g ± 0.19 for 
PCI2 + cisplatinum, and 0.13g ± 0.14 for PCI2 + doxorubicin. Statistical analysis 
revealed a trend toward reduced metastatic load in PCI2 alone treated mice but it did 
not reach statistical significance, whereas PCI2 combined with either chemotherapy 
resulted in significant lung metastases weight reduction (p < 0.05).  
Combined, these data further demonstrates that PCI2/chemotherapy combinations 
induce significant effects on the growth of STS lung metastasis and support 
consideration of this therapeutic regiment in the clinical setting. Importantly, these data 
formed the basis for a currently on-going phase I/II clinical study evaluating “PCI-
24781 in Combination With Doxorubicin to Treat Sarcoma” (ClinicalTrials.gov 
identifier: NCT01027910). 
Continuing our pre-clinical studies, as presented next, we sought to identify potential 
mechanisms contributing to HDACi sensitivity and especially to the noted 
chemosensitivity effects induced in response to HDAC inhibition.  
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Figure 13. PCI2 induces p21 expression 
independent of p53 status in STS cells. qRT-
PCR and RT-PCR showing a relatively early 
(4h treatment) increase in p21 mRNA 
expression in SKLMS1 (mutated p53) cells in 
response to PCI2. Modified from Figure 5, 
Lopez et al. Clin Cancer Res 2009;15:3472-
3483. 
Studies from our lab have previously demonstrated that Rad51 is commonly 
overexpressed in genetically complex STS contributing to the resistance of these 
malignancies to conventional chemotherapy; particularly doxorubicin (85). RAD51, a 
member of the RecA/Rad51 family of proteins, is a critical regulator of DNA double 
strand repair through homologous recombination (86, 87). Hypothesizing that modified 
Rad51 expression potentially contributes to the observed chemosensitivity effects of 
HDACis in STS, we set to confirm the effects of PCI2 on Rad51 expression. p21 
mRNA expression has been shown increase in response to HDAC inhibition with a 
variety of HDACi compounds in numerous cell lines of different histologies (50, 88). As 
a control, we opted to identify p21 mRNA expression in response to PCI2 in STS. 
qRTPCR and RTPCR demonstrated an early (4 h treatment) increase in p21 mRNA 
expression in SKLMS1 (p53 mut.) cells when treated with PCI2 (Fig. 13). We then 
verified Rad51 expression in response 
to PCI2. qRTPCR and RTPCR and WB 
analysis validated that PCI2 decreased 
RAD51 RNA and protein expression in 
STS cell lines, respectively (Fig. 14).  
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Figure 14. PCI2 induces decreased Rad51 expression in STS cells. A, qRTPCR (upper 
panel) and RTPCR (lower panel) showing a PCI2 (0.5μM) time-dependent decrease in 
RAD51 mRNA expression. B, PCI2 induced decrease in Rad51 protein expression is shown 
in STS cells via Western blotting. Modified from Figure 5, Lopez et al. Clin Cancer Res 
2009;15:3472-3483. 
Next, we aimed to define the mechanism by which HDACis inhibit RAD51 expression. 
First, to identify whether PCI2 affects RAD51 mRNA stability the, transcriptional 
inhibitor actinomycin D was used and RAD51 mRNA levels are determined with or 
without PCI2 treatment. RAD51 mRNA half-life was found to be comparable between 
treated and untreated cells, signifying that PCI2 does not have a direct effect on 
RAD51 mRNA degradation (data not shown). To further identify the effect of PCI2 on 
RAD51 transcription, we evaluated the recruitment of Poly II (RNA polymerase II) to 
the RAD51 gene. The recruitment of Poly II to the p21 gene was used as a control as 
we initially showed that PCI2 induced the upregulation of p21 RNA expression (Fig 
.13). A chromatin immunoprecipitation (ChIP) assay using an anti-Poly II antibody was 
employed showing that PCI2 treatment decreased Poly II recruitment to the RAD51 
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gene while it increased the recruitment of Poly II to the p21 gene (Fig. 15). ChIP assay 
was also used to determine the association of acetylated histone 3 (ac.H3) and 
histone 4 (ac.H4) to the RAD51 and p21 
promoters after PCI2 treatment. In PCI2 treated 
cells increase of both ac.H3 and ac.H4 
recruitment to the promoters of both genes 
were identified (Fig. 15). Together, these data 
indicate that PCI2 treatment induces the 
transcriptional repression of Rad51 
accomplished by an increase of acetylated 
histone 3 and 4 at the RAD51 promoter.  
We next investigated the repressive effect of 
PCI2 on RAD51 gene transcription using 
RAD51 reporter assays. A luciferase reporter 
construct of the RAD51 promoter region -403 to +63 was transiently transfected into 
STS cells tested. Cells treated with PCI2 showed a significant reduction of RAD51 
promoter activity. In contrast, a p21 reporter construct demonstrated increased p21 
promoter activity after PCI2 treatment (Fig. 16A). To further determine the RAD51 
promoter region required for PCI2-induced suppression, we utilized various 5’ 
truncated promoter regions. All constructs treated with PCI2 significantly showed 
reduced luciferase expression (Fig. 16B). Luciferase expression was also significantly 
Figure 15. ChIP showing decreased 
Pol II binding to RAD51 gene in 
response to PCI2 (0.5μM/24 h); in 
contrast increased Pol II binding to 
the p21 gene is seen. Binding of 
acetylated histones 3 and 4 to the 
RAD51 and p21 promoters is 
enhanced. No significant nonspecific 
IgG binding was observed; input 
DNA was used as loading control. 
Modified from Figure 6, Lopez et al. 
Clin Cancer Res 2009;15:3472-
3483.  
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Figure 16. A, PCI2 (0.5μM/24 h) induces suppression of RAD51 
promoter activity while it enhances p21 promoter activation; a −403 
bp RAD51 luciferase reporter assay was used. B, PCI2 induced 
RAD51 promoter repression is observed even when a reporter 
construct consisting of the proximal 50 bp, suggesting that the PCI2 
response element is located within this proximal region. Modified from 
Figure 6, Lopez et al. Clin Cancer Res 2009;15:3472-3483. 
reduced when the -50Luc region reporter was used, suggesting that the PCI2 
response element is at the proximal region of the RAD51 promoter. This promoter 
region was initially identified to include an E2F binding site which has been shown to 
be important in the transcriptional regulation of RAD51 (89). To determine if PCI2 
mediates its anti-Rad51 effects through this cis-regulatory element, the E2F binding 
site within the 
RAD51 reporter 
was mutated. 
DMSO treated cells 
demonstrated a 
decrease in 
luciferase readout 
when the E2F 
binding site was mutated, indicating that this site potentially mediates the transcription 
of Rad51. Interestingly, PCI2-induced reduction of luciferase expression noted when 
using a wild-type reporter construct was eliminated in cells transfected with the 
mutated E2F binding site construct (Fig. 17A). This data suggests that PCI2-mediated 
transcriptional repression of Rad51 occurs at the proximal region of the E2F binding 
site. E2F transcription factors consist of nine family members that can bind to this E2F 
site. Previously, E2F1 and E2F4 have been shown to bind the RAD51 promoter (89). 
Thus, E2F1 and E2F4 binding to the RAD51 promoter in response to PCI2 treatment 
was assessed. Using the ChIP assay, an increase in E2F1 binding was observed in 
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cells treated with PCI2, whereas a modest decrease of E2F4 binding was observed 
under this condition (Fig. 17B).Together, these data show that HDAC inhibition results 
in transcriptional repression of RAD51 mRNA expression. PCI2-induced decrease of 
RAD51 RNA represents a possible mechanism for the enhanced chemosensitivity 
observed in STS cells in vitro and in vivo.  
In summary, studies presented 
above demonstrate that human 
STS cells are highly sensitive to 
the effects of HDACis in vitro, 
resulting in cell cycle arrest and 
enhanced cell death. Most 
importantly, HDAC inhibition 
sensitized STS cells to the 
effects of chemotherapy; a pre-
clinical observation that is now 
being tested in the clinical 
setting. Multiple downstream 
effectors might contribute to HDACi anti-STS impact; amongst such is Rad51. PCI2-
induced decrease in Rad51 expression is a potential mechanism underlying HDACi 
chemosensitivity effects. While encouraging, it is important to recognize that 
genetically complex sarcomas are a heterogeneous malignancy cohort composed of 
multiple histologies. Taking this into account upon the completion of the studies above, 
Figure 17. A, Mutating the E2F binding site located 
within the first 50 bp of the RAD51 promoter construct 
resulted in decreased luciferase readout in untreated 
cells and most importantly abrogated the PCI2 
(0.5μM/24 h) induced RAD51 promoter repression. B, 
ChIP analysis showed enhanced E2F1 binding to its 
cis element in the proximal RAD51 promoter in 
response to PCI2 (0.5μM/24 h); a slight decrease in 
E2F4 binding is also observed. Modified from Figure 
6, Lopez et al. Clin Cancer Res 2009;15:3472-3483. 
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we decided to focus on a single histological subtype, MPNST and determine the 
effects of HDACi in this specific malignancy.  
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Table 5. Codelink oligo microarrays (GE Healthcare) containing a total 
of 2013 probes selected for known involvement in cancer to examine 
for PCI2-induced gene changes in STS cell lines. Cells were treated 
with PCI2 (0.5µM) or DMSO alone for 24 h, and RNA was subjected to 
analysis. A total of 33 genes exhibited reproducible change in 
expression (20 upregulated and 13 downregulated) in tested cell lines. 
Up-regulated genes are depicted in the upper panel (10 genes with the 
highest fold increase are shown), down-regulated genes are in the 
lower panel (10 genes with the highest fold decrease are shown). 
1.3 HDAC down-stream targets potentially contributing to the anti-STS and 
chemosensitivity effects of HDACis 
HDACs operate by deacetylation of histone and other non-histone proteins resulting in 
changes in chromatin condensation. HDAC inhibition thus leads to enhanced protein 
acetylation which consequently results in changes in gene expression. In the following 
set of studies we sought to identify HDAC inhibition induced genes that their 
expression changes might modulate the functional effects observed in STS cells after 
HDACi treatment. To that end we conducted gene expression profiling comparing the 
expression of genes in STS cells treated with PCI2 (for 4 and 24 h) to those treated 
with DMSO (control) only. The custom Codelink oligo microarrays (GE Healthcare) 
platform was 
utilized including 
probes for 2013 
genes known to 
be highly involved 
in tumorigenesis. 
A total of 33 
genes (1.6%) 
exhibited changed 
expression in 
response to PCI2 
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treatment: 20 were found to be overexpressed in 13 to be down-regulated (Table 5). 
Amongst the deregulated targets were included genes important for cell cycle 
progression: CDKN1A, CHEK1, CDK4; apoptosis: BIRC5, CASP9; transcription 
factors: ID2; DNA damage repair: BRCA1, RAD51.  
  
62 
 
Figure 18. A, PCI2 induces changes in gene expression in a panel of STS cell lines. B, 
PCI2 induces decreased CHK1 and increased CTGF expression in STS cells. RT-PCR 
(upper panel) and western blot (lower panel). 
Several genes were selected for array confirmation including CDKN1A (p21) and 
CTGF (demonstrating 4.6 and 16.2 fold increase, respectively) and CHEK1 
(demonstrating 5.3 fold decreased expression) (Table 5). RT-PCR and WB analyses 
confirmed the expected changes in the expression of these genes as was found by 
gene arrays (Fig. 18). Interestingly, one of the genes identified to be down-regulated in 
response to PCI2 treatment was RAD51. 
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Section 2: Aim 2: HDACis elicit anti-MPNST effects 
2.1 The effects of HDACis on MPNST growth in vitro and in vivo 
As described before, after showing the 
efficacy of HDAC inhibition in a panel of 
complex karyotypic STS subtypes, we 
then focused our studies of HDAC 
inhibition on a single, aggressive and 
dismal genetically complex STS 
subtype, MPNST. In this study, we used 
primary cultures of human normal 
Schwann cells (NSC) as a control, two 
sporadic MPNST cell lines (MPNST724 
and STS26T), and four NF1-associated 
MPNST cell lines (S462, ST88, T265, 
and MPNST642). The MPNST642 cell 
line was established in our laboratory 
(Fig. 19). Prior to initiating our studies 
we have first characterized our cell line 
panel (Table 6).  
Figure 19.  A, The cell line termed MPNST642 
originated from a recurrent MPNST located in the 
forearm of a 21 year old male diagnosed with NF1 
at childhood. IHC stains of original tumor are 
depicted (X200); H+E demonstrating the 
histomorphology of the tumor which stained 
positively for vimentin and focally for S100; B, 
MPNST642 cells have been growing in culture 
continuously for >60 passages (morphology is 
depicted, Geimsa staining, upper panel) and they 
exhibit anchorage independent growth (lower 
panel). DNA fingerprinting confirmed the cell 
origin to be from the human tumor and 
demonstrated that no cross contamination has 
occurred in culture; (continue to next page) 
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Figure 19.  (Continued from previous page) C, MPNST642 cells (2x106/mouse, s.c. injection) 
grow as xenografts in SCID mice: graph demonstrates growth rate (see also table below), 
histomorphology is similar to that of original patient tumor although S100 staining is negative 
(loss of S100 expression is known to occur with MPNST progression); D, Two additional 
MPNST cell lines of those used in our study (STS26T and MPNST724; 1-2x106/mouse) 
exhibit s.c. xenograft growth in SCID mice. Growth curves of all 3 available xenografts are 
shown together to enable comparison (left upper panel). H+E and IHC staining of xenografts 
are depicted (right upper panel) STS26T xenografts are negative for S100 while MPNST724 
are focally positive. In addition, tail vein injection of STS26T (1x106/mouse) results in 
reproducible lung metastasis – macroscopic and microscopic photographs are shown. The 
table summarizes the xenograft growth characteristics of all three human cell lines. STS26T 
are commonly used as a cellular model of sporadic MPNST and are widely accepted as a 
representative of this disease. MPNST724 have been kindly provided by Dr Jonathan 
Fletcher, the original diagnosis was made by a vastly experienced pathology team; S100 
positivity in MPNST724 xenografts further supports the MPNST origin of these cells. Modified 
from Figure S1, Lopez et al. Cancer Res 2011;71:185-196. 
Three pan-HDACis were used for this study: PCI2, SAHA, and MS275 to eliminate the 
possibility of compound specific off target effects. All three compounds induced a time- 
and dose-dependent growth inhibition that was most pronounced in a subset of 
MPNST cell lines tested. The graphs depict GI50s at 48 h; 4 MPNST cell lines were 
markedly sensitive to PCI2, with GI50s ranging between 0.1 and 0.35µM, whereas the 
2 additional cell lines (STS26T and MPNST724) were relatively 
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Figure 20. Growth-inhibitory effects (48 h) were determined via MTS assays, GI50s are 
depicted. One MPNST cell-line subset was highly sensitive to the effects of all 3 drugs 
(highest sensitivity to PCI2), whereas a second exhibited relative resistance. No significant 
effect on normal human Schwann cells’ (NSC) growth was noted in clinically relevant 
therapeutic doses. Modified from Figure 1, Lopez et al. Cancer Res 2011;71:185-196. 
Cell lines 
doubling 
time (h) 
NF1  
associated 
Ras  
active 
p53  
status 
grow  
in mice 
Lung  
metastases 
S462 24 negative Yes mut. No No 
ST88 36 negative Yes wt No No 
MPNST642 38 negative Yes wt Yes No 
T265 32 negative Yes mut. No No 
STS26T 19 positive No null Yes Yes 
MPNST724 27 positive Yes mut. Yes No 
 
r 
 
 
 
resistant exhibiting GI50s more than the clinically relevant dose (>1µM). NSCs were 
resistant to PCI2 growth inhibitory effects. Higher doses of SAHA and MS-275 were 
needed to achieve PCI2-equivalent MPNST growth inhibition; however, a similar 
Table 6. Human NF1-associated MPNST cell lines: S462, ST88, MPNST642, T265. Human 
sporadic MPNST cell lines: STS26T, MPNST724. Doubling time is depicted in hours. All 
NF1-associated cell lines have been confirmed for loss of NF1. Sporadic cell lines retain 
NF1. Ras activity was detected in all NF1-associated cell lines and MPNST724; STS26T did 
not exhibit Ras activity (Ras activity was detected using a Ras Activity assay Kit, Table 4). 
Sequence analysis determined p53 mutation status in all cell lines. Only one NF1-associated 
MPNST cell line grows s.c. in SCID mice (MPNST642). Both sporadic cell lines grow s.c. in 
SCID mice, but only STS26T develops lung metastases in SCID mice after tail veil injection. 
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response pattern was found for all these drugs, enabling MPNST cell designations to 
"sensitive" and "resistant" cohorts (Fig. 20).  
This same pattern of sensitivity/resistance to the compounds was observed using  
clonogenic assays (Fig. 21). We then determined if this “sensitive” and “resistant” 
effect on growth was due to HDACi-induced apoptosis. All three compounds induced 
marked apoptosis (Annexin-V/PI staining FACS analysis and western blotting for 
cleaved caspase 3) in ”sensitive” cell lines with little or no apoptosis in the ”resistant” 
cells (Fig. 22). HDACi-induced acetylation of target proteins was observed in all cells 
lines including normal Schwann cells despite variations on the effect on growth (Fig. 
23). Previous data have demonstrated that acetylation also occurs in normal cells 
(known to be resistant to HDACi effects), suggesting that even though HDACis reach 
Figure 21. Clonogenic assays showed a similar pattern of response to HDACis The 
respective graphs represent the number of colonies counted in experiments; repeated three 
times. Modified from Figure 1, Lopez et al. Cancer Res 2011;71:185-196. 
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and inhibit their targets, additional mechanisms play a role in HDACi-mediated 
sensitivity and resistance (81). 
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We then tested the in vivo effect of PCI2 (this compound was selected due to its 
enhanced effect in vitro) on therapeutic “sensitive” and “resistant” human xenografts. 
Similar to the effects observed in vitro, MPNST642 xenografts were highly sensitive to 
the inhibitory growth effects of PCI2, while only a minimal effect on tumor growth 
occurred in MPNST724 and STS26T xenografts (Fig. 24A). Of note, marked effects 
on growth and tumor weight (p = 0.00016 and 0.0004, respectively) were noted in the 
MPNST642 experiment even when a relatively low therapeutic dose (25 mg/kg BID) 
was used. In contrast, no statistically significant impact (p > 0.05) was found in 
Figure 22. Marked apoptosis was noticed in "sensitive" cell lines but not in "resistant" cell 
lines [Annexin V/PI staining FACS analyses (48 h) and cleaved caspase-3 WB]. Modified 
from Figure 1, Lopez et al. Cancer Res 2011;71:185-196. 
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Figure 23. A time- and dose-dependent increase in target protein acetylation was shown 
after treatment with either of the compounds in all cell lines (including NSC) independent of 
growth inhibitory response (MS-275 is a selective HDAC1/HDAC2 inhibitor and does not 
affect tubulin acetylation). Modified from Figure 1, Lopez et al. Cancer Res 2011;71:185-196. 
MPNST724 and STS26T experiments even when a high dose of PCI2 (50 mg/kg BID) 
was utilized (Fig. 24A). IHC analysis of the tumors from both xenografts reflected this 
difference in sensitivity and resistance (Fig. 24B). PCI2-treated MPNST642 xenografts 
had a decrease in Ki67 staining (cell proliferation) with an increase in TUNEL positive 
cells (p = 0.008 and 0.0008). IHC analysis in the MPNST724 xenografts showed an 
opposite effect; no discernible change in Ki67 and TUNEL among vehicle and treated 
cohorts. This data further confirms HDACi-induced sensitivity and resistance in NF1-
associated and sporadic MPNST cells, respectively.   
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Figure 24. SCID mice bearing MPNST642 and MPNST724 xenografts were treated with 
PCI2 (PCI2; 25 mg/kg/d and 50 mg/kg/d, respectively) or vehicle (10 mice/group). Tumor 
growth and weight curves are depicted showing that PCI2 abrogated the growth of 
MPNST642 tumors (p = 0.00016 and 0.0004 for tumor size and weight, respectively), but not 
of MPNST724 tumors although treated with a higher drug dose; B, H&E showed enhanced 
tumor necrosis in MPNST642 PCI2-treated tumors, decreased tumor proliferation (Ki67; p = 
0.008), and increased apoptosis (TUNEL; p = 0.0008). No significant differences were found 
for MPNST724 xenografts. * statistically significant effects; p < 0.05. A similar experiment 
was conducted using STS26T xenografts (data not shown) exhibiting minimal effects of 
PCI2; results identical to those observed when treating MPNST724 tumors. Modified from 
Figure 2, Lopez et al. Cancer Res 2011;71:185-196. 
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2.2 Potential mechanisms of sensitivity  
Our results thus far suggest that a subset of MPNST cells are highly sensitive to 
HDACi effects. Unraveling the mechanism underlying this sensitivity is highly 
interesting from the biological/molecular perspective and can potentially be important 
for the appropriate selection of patients to HDACi-based “smart” clinical trials. First, we 
asked whether HDACi sensitivity is dependent of all tumor growth rates. Table 7 
depicts the average doubling times of our MPNST cell line panel. As can be 
ascertained from this data, no direct correlation between HDACi sensitivity and growth 
rate could be identified. Next, we sought to determine whether p53 mutational status 
possibly correlates with HDACi sensitivity. HDACis are known to induce their effects, 
at least in part by p53 activation (90). However, MPNSTs are known to commonly 
harbor p53 mutations (91). To that end, we hypothesized that mutated p53 cells might 
be more resistant to the effects of HDACis. p53 mutational status of our panel of 
MPNST cell lines is depicted in Table 7. No direct correlation between p53 status and 
HDACi sensitivity could be identified as the most sensitive cell line (S462) and the 
least sensitive cell lines (MPNST724 and STS26T) were found to harbor p53 
mutations. Furthermore, to evaluate whether the effects of HDACi in our cells are 
exerted at least in part through p53, wild-type p53 ST88 and p53 null STS26T cell 
lines were used. Knockdown of p53 combined with PCI2 did not enhance apoptosis 
compared to non-target control in ST88 cells, suggesting that the absence of p53 does 
not confer resistance to pan-HDACi. Overexpression of p53 combined with PCI2 did 
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not enhance apoptosis compared to control in STS26T cells, suggesting that HDACi 
does not enhance sensitivity via p53 (Fig. 25).  
 
Intriguingly, when we evaluated our 
results we noticed that all 
“sensitive” cell lines are NF1-
associated while the “resistant” cells 
are sporadic MPNSTs (Fig 26A). 
While this observation has to be 
viewed with caution due to the 
limited cell line number available, 
we thought it is worthy of further 
investigation. Of note, this unique 
response pattern was not observed 
when we tested with doxorubicin or 
other molecularly targeted anti-cancer therapies (e.g. the TKR inhibitor, XL184) (data 
not shown). Somatic NF1 loss has been suggested in another STS histological 
subtype, pleomorphic liposarcoma (PLS) (92); we evaluated our human PLS cell line 
cohort, finding that at least one of the three cell lines (Lisa2) exhibited NF1 expression 
loss (data not shown). Interestingly, this cell line was also the most sensitive to PCI2. 
While not directly related to these MPNST-focused studies, this observation further 
suggests a potential role for NF1 loss as an HDACi response biomarker and offers an 
Figure 25. NF1-associated MPNST cells are highly 
sensitive to HDACi; sensitivity is independent of p53 
mutational status. p53 siRNA knockdown in cells 
harboring the wild type gene (ST88) did not confer 
HDACi resistance and transient p53 over-
expression in null cells (STS26T) via adeno-p53 
transfection did not enhance HDACi sensitivity in 
these resistant cells. Modified from Figure S2, 
Lopez et al. Cancer Res 2011;71:185-196. 
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Figure 26. A, All HDACi sensitive cells in our 
study were found to be NF1 associated (WB 
depicting loss of neurofibromin protein 
expression) while resistant cells were of 
sporadic MPNST origin, expressing NF1. NF1 
loss is the hallmark of NF1-associated 
MPNST. Several studies have identified 
somatic NF1 mutations to occur in a subset of 
sporadic MPNSTs, although not uniformly in 
all cases (e.g. Bottillo et al. J Path, 2009: 217; 
693-710). The exact prevalence and 
importance of NF1 loss in sporadic MPNST 
tumorigenesis is currently unknown. B, NF1 
knockdown in sporadic cell line STS26T 
enhanced HDACi-induced pro-apoptotic 
effects, further confirming a role of NF1 in 
response to the effects of HDAC inhibition. 
additional cellular model for basic NF1 studies. To determine whether NF1 loss does 
contribute to HDACi sensitivity, we knocked down NF1 in MPNST724 and STS26T 
cells using specific siRNA constructs (Fig. 26B); Neurofibromin loss resulted in 
increased apoptosis in response to HDACi. Together, these data demonstrate a 
potential role for NF1 loss in MPNST sensitivity to the pro-apoptosis effects of 
HDACis.  
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Section 3: Aim 2: (Macro)Autophagy as a mechanism of HDACi resistance in MPNST 
 
3.1 HDACis induce autophagosome accumulation in MPNST cells  
It is critical to determine the potential mechanisms contributing to the observed 
tolerance of some MPNST cells to HDAC inhibitors in order to develop more effective 
HDACi-based therapeutic combinations. To evaluate structural changes in “resistant” 
cells induced by HDACi, transmission electron microscopy (TEM) was utilized. Many, 
autophagosomal structures of various size were observed in PCI2 treated cells, with 
no morphological features indicative of apoptosis or necrotic cell death (Fig. 27). The 
Figure 27. TEM images showing ultrastructural changes in MPNST cells in response to PCI 
(0.5µM/24 h). A large number of autophagic vesicles were identified (arrows) without 
evidence of chromatin condensation, nuclear membranes remained intact further supporting 
lack of apoptotic effect. Modified from Figure 3, Lopez et al. Cancer Res 2011;71:185-196. 
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presence of HDACi-induced autophagosome accumulation was further established 
when western blotting for the presence of LC3B conversion and the expression of 
LC3B-II. An increased expression of LC3B-II is indicative of an increase in 
autophagosome number; all three HDACis enhanced LC3B-II expression (Fig. 28). 
STS26T and MPNST724 were stably transduced to express GFP-LC3 and these were 
treated with HDACi and monitored via fluorescent microscopy. HDACi treatment 
induced an increase in GFP-LC3 puncta, representative of autophagosome 
accumulation (Fig. 29). HDACi-induced autophagosomal accumulation was also 
observed in vivo. 
GFP-LC3 transduced 
MPNST cells were 
injected s.c. into 
SCID mice and when tumors reached 1 cm, mice were treated with PCI2 for 4 days. 
On the 5th day a final dose was administered and tumors were collected after 2, 4, and 
6 h. Western blot analysis of the tumor samples showed increased LC3B-II conversion 
in a time-dependent manner (Fig. 30). Furthermore, TEM identified autophagosome 
accumulation in tumor cells in vivo after treatment with PCI2 (Fig. 30). 
Interestingly, TEM analyses have demonstrated the potential accumulation of 
autophagosomes in NF1-associated, HDACi sensitive, MPNST cells in response to 
therapy. However, in contrast to resistant cells, signs of apoptosis were noted in these 
cells on TEM (chromatin condensation, membrane blebbing, etc.). Additional assays, 
Figure 28. Increased LC3B-II expression (normalized to actin; 
densitometry values are depicted) was noticed after HDACi. 
Modified from Figure 3, Lopez et al. Cancer Res 2011;71:185-196. 
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as per above, confirmed autophagosome accumulation in this MPNST cell line cohort 
(Fig. 31, 32). 
Together, these experiments demonstrated that HDACi-induced autophagosomal 
accumulation occurs in all tested MPNST cell lines. Autophagosome accumulation is 
not necessarily a mark of induced autophagy as it can signify either enhanced 
autophagic flux or blocked, incomplete autophagy. Multiple additional experiments are 
required in order to determine the implications of the above observations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Cells stably transduced to express GFP-
LC3 exhibited increased GFP puncta in response to 
HDACis. Modified from Figure 3, Lopez et al. Cancer 
Res 2011;71:185-196. 
Figure 30. WB of STS26T 
xenografts’ protein treated with PCI2 
(50 mg/kg/d) harvested 2, 4, and 6 h 
after final dose showed a time-
dependent increase in LC3B-II 
expression. TEM images showing 
autophagosomal structures in 
STS26T xenografts. Samples used 
for the experiments shown here are 
from the same in vivo therapeutic 
experiment. 
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Figure 31. TEM images showing ultrastructural changes in 
NF1-associated MPNST cells in response to PCI2 
(0.5μM/24 h). As seen in “resistant” cells (Fig. 28) a large 
number of autophagic vesicles can be found after HDACi 
treatment. However, prominent features of apoptosis such 
as chromatin condensation and loss of nuclear membranes 
are also evident. Modified from Figure S3, Lopez et al. 
Cancer Res 2011;71:185-196. 
Figure 32. Increased LC3B-II 
expression was noticed after 
treatment of “sensitive cells” 
with any of the HDACis. ST88 
GFP-LC3 exhibited increased 
GFP puncta in response to 
HDACi treatment. Modified 
from Figure S3, Lopez et al. 
Cancer Res 2011;71:185-196. 
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Figure 33. AO staining demonstrated increased AVOs in PCI2 treated (0.5uM/24 h) sporadic 
and NF1-associated MPNST cells compared to control treated cells, as was further 
confirmed via FACS analysis. Modified from Figure 3 and S3, Lopez et al. Cancer Res 
2011;71:185-196. 
3.2 HDACis induce productive autophagy in MPNST cells in vitro and in vivo 
 As stated above, additional assays are required to distinguish between enhanced 
autophagic flux (productive autophagy) and blocked autophagy. First, staining with the 
lysotropic compound acridine orange revealed an increase in acidic vesicular 
organelles in PCI2 treated cells compared to control DMSO treated cells; microscopy 
and FACS analysis both confirmed this observation (Fig. 33). 
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 Increased acridine orange staining was seen in both “resistant” and “sensitive” cells 
suggesting enhanced productive autophagy in response to treatment. This assay, 
however, is not sufficient to conclusively determine productive autophagy and 
additional experiments using inhibitors of the final stages of autophagy (Bafilomycin A1 
[BFA] and chloroquine [CQ]) are usually needed. Pretreatment (1 h) of MPNST cells 
with either lysosome inhibitor followed by PCI2 for 24 h resulted in a higher expression 
of LC3B-II compared to control, BFA or CQ alone, and PCI2 alone, providing evidence 
for enhanced productive autophagy in response to PCI2 (Fig. 34). Those effects were 
noted in both “resistant” (Fig. 34A) and “sensitive” (Fig. 34B) MPNST cell lines. 
Similarly, when GFP-LC3 transduced cells were treated with BFA or  
CQ, HDACi, and BFA/CQ combined with HDACi, an increase of GFP cleavage from 
LC3B was observed in PCI2 treated cells compared to other treatments (Fig. 35A).  
 
 
 
 
 
Figure 34. Sporadic (panel A) and NF1-associated MPNST cells (panel B) were pretreated (1 
h) with low doses of the inhibitors BFA (1 nM) or CQ (1 uM) prior to PCI2 treatment (24 h). 
Additional increased LC3B-II expression in response to PCI2 was noticed in the presence of 
these inhibitors. Modified from Figure 3 and S3, Lopez et al. Cancer Res 2011;71:185-196. 
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Together, these assays support HDACi-induced productive autophagy in MPNST cells 
in vitro. GFP-LC3 xenografts were also treated with PCI2, chloroquine, and the 
combination (mice were treated with chloroquine 1 day prior to combining with PCI2). 
Western blot analysis of the tumor samples showed an increase cleaved GFP in PCI2 
treated mice whereas pretreatment with CQ inhibited PCI2-induced GFP cleavage 
(Fig. 35B). This data revealed that HDACi-induced autophagy can be recapitulated in 
vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. A, MPNST724 GFP-LC3 cells (left panel) and ST88 GFP-LC3 (right panel) were 
pretreated (1 h) with CQ (1 uM) prior to PCI2 treatment (24 h). GFP cleavage was found in 
response to HDACi and was blocked by pretreatment with CQ. Free GFP expression was 
found in response to PCI2 treatment. Chloroquine blocked HDACi-induced increases in free 
GFP. B, MPNST724 GFP-LC3 xenografts were treated with PCI2, CQ, or their combination. 
Free GFP expression was found in response to PCI2 treatment. Chloroquine blocked HDACi-
induced increases in free GFP. Modified from Figure 3 and S3, Lopez et al. Cancer Res 
2011;71:185-196. 
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3.3 Autophagy is a mechanism of therapeutic resistance in MPNST 
The role of drug-induced autophagy in cancer remains controversial, whether this 
process contributes to cell death or is a mechanism of resistance might be a cell-
context, -compound, -specific consequence (93, 94). To evaluate the role of HDACi-
induced autophagy in MPNST we evaluated the impact of autophagy blockade by 
genetic (i.e. siRNA) and pharmacological inhibition on the HDACi therapeutic 
response. Knockdown of beclin 1, ATG5, and ATG7, genes essential for the induction 
of autophagy, was combined with PCI2. Knockdown of these genes, as expected, 
inhibited PCI2-induced LC3B conversion (i.e. autophagy) and most importantly 
resulted in enhanced apoptosis compared to knockdown or PCI2 treatment alone (Fig. 
36-38). Enhanced apoptosis was noted in both “resistant” and “sensitive” MPNST cell 
lines; a lower PCI dose was used for the later.   
 
 
 
 
 
 
 
 
 
 
Figure 36. Anti-Beclin siRNA (20 nM pool) knockdown in sporadic (A) and NF1-associated 
MPNST cells (B) was confirmed by WB and autophagy blockade was validated using LC3B-II 
WB. Enhanced apoptosis in response to PCI2 (sporadic cells 0.5 uM/24 h; NF1-associated 
cells (0.1 uM/24 h) was determined by PARP cleavage and Annexin-V/PI FACS analysis. 
Modified from Figure 4 and S3, Lopez et al. Cancer Res 2011;71:185-196. 
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Figure 37. Anti-ATG5 siRNA (20nM pool) knockdown in sporadic (A) and NF1-associated 
MPNST cells (B) was confirmed by RT-PCR and autophagy blockade was validated using 
LC3B-II WB. Enhanced apoptosis in response to PCI2 (sporadic cells 0.5uM/24h; NF1-
associated cells (0.1uM/24 h) was determined by PARP cleavage and Annexin-V/PI FACS 
analysis. Modified from Figure 4 and S3, Lopez et al. Cancer Res 2011;71:185-196. 
Figure 38. Anti-ATG7 siRNA (20nM 
pool) was confirmed by WB and 
autophagy blockade was validated 
using LC3B-II WB. Enhanced apoptosis 
in response to PCI2 (0.5uM/24 h) was 
determined by PARP cleavage and 
Annexin-V/PI FACS analysis. Modified 
from Figure 4, Lopez et al. Cancer Res 
2011;71:185-196. 
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We next evaluated the effect of pharmacological inhibition of autophagy combined with 
HDACi. Again, we used BFA and/or CQ to inhibit lysosomal-mediated degradation of 
HDACi-induced autophagosome content. Monotherapy with BFA/CQ and PCI2 had no 
effect on the clonogenic potential of MPNST cell lines, but combination of these 
compounds resulted in a significant reduction in colony forming capacity (Fig. 39).   
 
 
 
 
 
 
 
 
Combination therapy also resulted in enhanced apoptosis compared to BFA/CQ and 
PCI2 alone (Fig. 40). These effects were noted in both “resistant” and “sensitive” 
MPNST cell lines; a lower PCI2 dose was utilized for the later. Taken together, our 
data strongly demonstrates that autophagy blockade enhances the pro-apoptotic 
effects of HDACis in MPNST. This occurs in both cells that are relatively resistant to 
HDACi-induced apoptosis as well as cells that are sensitive to these effects. In the 
later scenario, combining autophagy blockade with even low doses of HDACis induces 
marked cell death.  
 
Figure 39. Pharmacologic autophagy 
inhibition was achieved using BFA 
and CQ. None of the compounds 
alone significantly affected the 
clonogenic capacity of STS26T or 
MPNST724; however, significant 
effects were noticed after CQ (1uM) 
or BFA (1nM) pretreatment of cells 
(1 h) followed by PCI2 for 24 h (p < 
0.05). Modified from Figure 4, Lopez 
et al. Cancer Res 2011;71:185-196. 
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While the above results are highly promising, all of these observations were made 
using cells growing in culture. At this stage it was thus critical if superior effects of 
HDACi/autophagy blockade can be recapitulated in vivo. To that end, mice harboring 
STS26T and MPNST724 xenografts were allocated into 4 treatment arms when 
tumors reached ~5 mm3: vehicle, CQ, PCI2, CQ combined with PCI2. In the 
combination treatment, mice were treated with CQ 24 hr prior to combining with PCI2. 
As in previously described experiments (see Fig. 25), the efficacy of PCI2 as 
monotherapy was minimal as compared to vehicle control. Similarly, Chloroquine 
alone did not significantly impact tumor growth. However, combination therapy 
resulted in significant tumor growth inhibition in both xenograft models compared to 
vehicle or either compound alone (Fig. 41). MPNST724 xenograft volumes and 
weights at study termination were: control 1576.1 mm3 ±573.6 and 1.3 g ±0.2; PCI2 
1131.1 mm3 ±257.7 and 1.24 g ±0.1; Chloroquine 925.3 mm3 ±201.8 and 1.1 g ±0.1; 
and combination 209.2 mm3 ±44.8 and 0.25 g ±0.1 respectively. STS26T tumor 
volumes and weight at study termination were: control 1242.8 mm3 ±120 and 1.4 g 
Figure 40. Pretreatment with BFA or CQ combined with PCI2 markedly increased apoptosis. 
Modified from Figure 4 and S3, Lopez et al. Cancer Res 2011;71:185-196. 
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±0.2; PCI2 985.5 mm3 ±143.8 and 1.1 g ±0.1; Chloroquine 1030.3 mm3 ±144 and 1.2 g 
±0.2; and combination 171.7 mm3 ±123 and 0.24 g ±0.1 respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Tumor growth curves/weight bars showing a significant impact of PCI2 + CQ 
combination on MPNST724 and STS26T growth (p = 0.04 and p = 0.03, respectively). No 
significant effect was noted after either compound alone. *, statistically significant effects; p < 
0.05. Modified from Figure 5, Lopez et al. Cancer Res 2011;71:185-196. 
Figure 42.  TUNEL assay of samples from Fig. 43. Significant increase in apoptosis (TUNEL 
staining) was observed in combination-treated xenografts (p < 0.05). *, statistically significant 
effects; p < 0.05. Modified from Figure 5, Lopez et al. Cancer Res 2011;71:185-196. 
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Immunohistochemical analysis revealed that combination treated tumors had a 
significant increase in TUNEL positive cells compared to vehicle or either compound 
alone (Fig. 42).  
While the above experiment evaluated the effects of treatment on local MPNST 
xenograft growth it is critical to assess if this therapeutic regiment affects MPNST lung 
metastasis growth. Limited by the lack of spontaneous MPNST lung metastasis mouse 
models, we utilized an experimental model where STS26T cells are injected i.v. into 
the tail vein. Established lung metastasis develop within 2 weeks after injection, thus 
treatment was initiated at that time. Similar to the local growth xenograft models, 
combination of CQ with PCI2 significantly inhibited the growth of STS26T lung 
metastases compared to either drug alone (Fig. 43). All mice in this therapeutic 
experiment had observable macroscopic lung metastases, however, the number of 
macroscopic lesions was severely reduced in combination therapy mice compared to 
vehicle, PCI2 and Chloroquine alone. The average number of macroscopic lung 
metastases were: Vehicle 9.6 ±1.8, PCI2 8.2 ±1.7, Chloroquine  8.5 ±1.7, combination 
2.1 ±1.1. This difference between vehicle, PCI2 and Chloroquine alone compared to 
combination was highly significant (p >0.001). Average lung weights from each group 
also depicted these significant differences: Vehicle 0.6 g ±0.1, PCI2 0.4 g ±0.1, 
Chloroquine 0.4 g ±0.1, combination 0.2 g ±0.1. Cumulatively, these data confirm that 
autophagy blockade sensitizes MPNST xenografts to the pro-apoptotic effects of 
HDACi in vivo. 
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Figure 43. STS26T lung metastases bearing mice were treated with PCI2, CQ, or their 
combination. A significant decrease in number of visible metastasis (left graph) and average 
lung weight (right graph) were found in the combination therapy group (p < 0.05) but not after 
treatment with either agent alone. *, statistically significant effects; p < 0.05. Modified from 
Figure 5, Lopez et al. Cancer Res 2011;71:185-196. 
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Section 4: Aim 2: Molecular mechanisms underlying HDACi induced autophagy in 
MPNST 
4.1 Autophagy gene array results and confirmation 
Unraveling the molecular mechanisms underlying the development of productive 
autophagy in response to HDACi are highly important. This information can not only 
enhance our current knowledge of the autophagy process but can hopefully result in 
the identification of molecules that can be targeted in combination with HDACi to 
achieve improved anti-MPNST therapeutic effects. This is especially critical when 
realizing that Chloroquine is not exclusively an autophagy inhibitor, having multiple “off 
target” effects. To identify potential molecules contributing to HDACi-induced 
autophagy, we used a focus PCR-based autophagy array (this platform consists of 
primers targeting 84 genes known to play a role in autophagy, 56). RNA was extracted 
from MPNST cells treated with PCI2 (0.5uM, 24 h) or with DMSO alone and autophagy 
related gene expression changes were determined. Treatment with PCI2 induced the 
overexpression of 4 genes and the downregulation of 5 genes in all 4 cell lines tested. 
Overexpressed genes CXCR4, TMEM74, and IRGM and downregulated NF-kB were 
chosen for array validation. Quantitative RTPCR demonstrated a dose-dependent 
increase or decrease in the RNA expression of the selected genes after treatment with 
PCI2 (Fig. 44). These PCI2-induced changes in RNA expression also occurred in 
samples obtained from in vivo therapeutic experiments (Fig. 45). This data identified a 
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variety of HDACi-modified genes potentially important in HDACi-induced autophagy, 
warranting additional study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. A focused autophagy PCR array identified several genes to be reproducibly 
deregulated in response to PCI2 (0.5uM/24 h). A concordant dose-dependent 
increase/decrease in corresponding RNA expression levels was identified (qRTPCR) in both 
cell lines after treatment with PCI2 (24 h). Modified from Figure 6, Lopez et al. Cancer Res 
2011;71:185-196. 
Figure 45. An increase in IRGM, CXCR4, and TMEM74 mRNA and a decrease in NF-kB 
mRNA levels were identified by qRTPCR and RTPCR in xenograft tissues retrieved from 
experiments described earlier. Modified from Figure 6, Lopez et al. Cancer Res 
2011;71:185-196. 
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4.2 IRGM as an HDACi target enhancing  
Among the genes selected for validation, IRGM exhibited the highest increase in 
HDACi-induced RNA expression, and was thus chosen for further evaluation of its 
potential role in HDACi-induced autophagy. To determine whether the observed 
increase in IRGM is PCI2 specific or is a more general response to HDACi in our cells 
we evaluated its expression in response to SAHA and MS-275; both compounds 
enhanced the expression of this gene. WB analysis further demonstrated that the 
effects on IRGM mRNA were also recapitulated in protein expression levels (Fig. 46).  
 
 
 
 
 
 
Next, the impact of IRGM on HDACi-induced autophagy was evaluated. IRGM was 
knocked down in MPNST cells using siRNA constructs; KD was confirmed by RTPCR. 
These cells as well as cells transfected with non-targeting siRNA constructs (used as 
controls) were treated with PCI2. WB analyses confirmed that IRGM KD inhibited LC3 
conversion and LC3-II expression in MPNST cells in response to PCI2. Most 
importantly, IRGM KD induced apoptosis in MPNST cells in response to HDAC 
inhibition (Fig. 47). Together, we found that HDACi-induced expression of IRGM 
Figure 46. An increase in IRGM 
mRNA was also identified by in 
response to SAHA and MS-275 
(1uM/24 h). Furthermore, a PCI2-
induced increase in IRGM protein 
was observed. Modified from Figure 
6, Lopez et al. Cancer Res 
2011;71:185-196. 
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enhances productive autophagy and inhibition of this protein enhances the pro-
apoptotic effects of the drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. IRGM siRNA knockdown 
(20nM, pool) resulted in PCI2 
(0.5uM/24 h)-induced autophagy 
blockade (decreased LC3B-II 
expression) and in enhanced PCI2-
induced apoptosis. Modified from 
Figure 6, Lopez et al. Cancer Res 
2011;71:185-196. 
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Section 5: Aim 3: Effects of HDAC8 inhibition on MPNST 
5.1 Effects of HDAC8is on human and murine MPNST cells in vitro 
Collectively, we have shown that MPNSTs are highly sensitive to the effects of pan-
HDACi when administered as single agents or in combination with autophagy 
inhibitors. However, data stemming from clinical studies suggest that pan-HDACi have 
a narrow therapeutic window due to toxicity. Development of HDAC isoform-specific 
inhibitors might increase this therapeutic window by eliminating unwarranted side 
effects elicited by blocking multiple HDAC enzymes. While no specific inhibitors are 
currently available for HDACs 1, 2, or 3, recently, highly selective compounds blocking 
the activity of the forth isoform, HDAC8, have been developed. In these final set of 
experiments, we sought to evaluate the effects of such inhibitors: PCI-34051 and its 
derivative PCI-48012; the later a little less selective but having better PK/PD properties 
making it ideal for in vivo studies. For these studies, in addition to testing the effects on 
our panel of human MPNST cell lines, we have also utilized several murine MPNST 
cell lines derived from tumors spontaneously developed in the MPNST GEM model 
(cis NF1-/+/p53-/+). Two such cell lines (MPNST6IEP4 and MPNST6IEP) were provided 
by Dr. Luis Parada (UT Southwestern, Dallas, TX) and two additional ones (NF1-TG-
05 and NF1-TG-09) were developed in our laboratory. HDAC8 inhibition, unlike the 
inhibition of other HDACs, was previously demonstrated to not induce the acetylation 
of histones and/or tubulin. To confirm that PCI3 and PCI4 do not inhibit other HDACs 
we evaluated the expression of acetylated histones and tubulin via WB. As shown in 
Fig. 48, induction of histones 3 and 4 and tubulin acetylation was observed in human 
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as well as murine MPNST cells after PCI2 treatment but not in response to PCI3 or 
PCI4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
This data confirms with previously published data demonstrating that histone 3 and 4 
and tubulin are not deacetylation targets of HDAC8, at least in certain cellular models 
(66, 68). Despite these results, HDAC8 has been shown to deacetylate core histone 
proteins (61, 63, 64). KrennHrubec et al. showed that compound 2, a ‘linkerless’ 
hydroxamate-derived compound with high affinity to HDAC8, when used at high doses 
(100uM) induced the expression of acetylated histone 4 and α-tubulin in HeLa and 
HEK293 cells. Importantly, compound 2 at 0.8uM was shown to have minimal 
Figure 48. Western blot analysis showing HDAC8i (PCI3 and 4, 5uM/24 h) do not induced 
increases in histone 3, histone 4, and tubulin acetylation in human (A) and murine-derived 
(B) MPNST cells. PCI2 (0.1 – 0.5uM/24h) was used as a positive control for these 
experiments. 
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Figure 49. MTS assays demonstrating the effect of HDAC8 inhibition (96 h) on human (A) 
and murine-derived (B) MPNST cell growth. Murine-derived MPNST cells exhibited marked 
sensitivity to both HDAC8i compared to human MPNST cell lines.  Murine MPNST cell 
growth was abrogated with lower doses compared to human MPNST cell. Although STS cell 
growth inhibition was seen with both agents, a more significant response to PCI2 was 
observed in cells tested (as previously demonstrated). Black bars depict PCI3, grey bars 
depict PCI4. 
inhibition of HDAC6, a HDAC known to specifically deacetylate tubulin (70). Our data 
using PCI3/4 suggests, at least in our MPNST models, that HDAC8 may serve in a 
role independent of histone modification. Similar to the work done by Krennhrubec and 
colleagues, it will be important to identify if PCI3/4 can induce histone and tubulin 
acetylation in our MPNST cells at higher doses than currently used. Of note, 
Balasubramanian et al., showed that PCI-34051 (PCI3) did not induce the acetylation 
of histones or tubulin in Jurkat cells at doses < 25uM (68). Next, we proceeded to 
determine whether HDAC8 inhibitors exhibit any effects on the growth of MPNST cells. 
MTS assays (96 h) demonstrated a dose-dependent growth inhibitory effect of PCI3/4  
on human and murine-derived MPNST using doses in the micromolar range (Fig 49).  
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Effective doses of PCI3 were similar to previously reported effective doses in T-cell-
derived leukemia cell lines (68). Interestingly, PCI3 was not shown to induce 
cytotoxicity in solid tumor cell lines of various histology at doses equal or less than 
5uM (68). However, Compound 2 was shown to abrogate the growth of neuroblastoma 
cell lines (69, 71). Notably, both neuroblastoma and MPNST originate from neural 
crest cells. Similarly to the pattern noticed with pan-HDACis, NF1-associated cells, at 
least S462, was more sensitive to both HDAC8is compared to sporadic MPNST cell 
lines independent of p53 mutational status or growth rate. S462 had a 50% reduction 
in cell growth at dose ranges of 1-5uM for both HDAC8i compounds. MPNST642 and 
STS26T both had a 50% reduction in cell growth at dose ranges of 5-10uM and 1-5uM 
for PCI3 and PCI4, respectively. MPNST724 had a 50% reduction in cell growth at 
dose ranges of 5-10uM for both HDAC8i compounds (Fig. 49A). Among human and 
murine MPNST, the murine MPNST cells were more sensitive to HDAC8is compared 
to human MPNST and required lower doses of both compounds (Fig. 49B). This 
pattern seen in human MPNST cells was recapitulated using a clonogenic assay (Fig. 
50). The clonogenic capacity of murine-derived MPNST cells was very low where 
colonies would not form when 100-500 cells per well (in a 6-well culture plate) were 
plated and cultured for >10 days. For human MPNST cells, approximately 100 cells 
are all that are required to successfully grow colonies. Due to this unforeseen 
characteristic of murine-derived MPNST cells, clonogenic assays were not conducted. 
The variation of effect between PCI3 and PCI4 may possibly be due to the nominal 
affinity of PCI4 has to HDAC6 compared to PCI3 (data not shown). Overall, these data  
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Figure 50. HDAC8i abrogate 
human MPNST cell colony 
formation capacity. 100 – 200 cells 
were initially plated for each cell 
line. 24 h after plating, PCI3/4 
(5uM) was added to the treatment 
wells continuously for 10 – 14 
days. Right panel of each cell line, 
number of colonies counted in 
experiments. Murine-derived 
MPNST cells failed to grow 
colonies at 100 – 500 cells per 
well, therefore the clonogenic 
capacity of murine MPNST cells 
are yet to be determined. 
demonstrate human and murine-derived MPNST growth inhibition in response to the 
pharmacological inhibition of HDAC8. 
To further investigate the role of HDAC8 inhibition on MPNST growth, we next tested 
the effect of both compounds on MPNST cell cycle. To evaluate PCI3/4 effect on cell 
cycle without the potential marked increase in sub-G1 fractionation, the MPNST cells 
(human and murine) were tested with 5uM of both compounds for 48h. From here on, 
these preliminary studies utilized 2 human MPNST cell lines (one NF1-associated and 
one sporadic cell line) and 2 murine-derived MPNST cell lines (NF1-TG-09 developed 
in our laboratory and MPNST6IEPVI developed by Dr. Luis Parada). PCI2 (used as 
control) did not induce an increase in S-phase, but rather a decrease compared to 
PCI3/4. PCI2 induced an increase in G1 and G2 in S462 and a marked increase in G2 
in STS26T cells. PCI2 induced a modest increase in G1 and G2 in MPNST6IEPVI 
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cells. Interestingly, cell cycle analysis revealed a common pattern of HDAC8i-induced 
S-phase cell cycle arrest, regardless of p53, NF1 status, and species (Fig. 51).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. PI staining/FACS analyses showing the effect of HDACis (PCI2 0.5uM/48 h, 
PCI3/4 5uM/48 h) on human and murine-derived MPNST cell cycle progression. PCI2 
reduced S-phase with a modest increase in G1 and G2 in S462 cells. STS26T exhibited a 
PCI2-induced G2 arrest. The effect of PCI2 on murine-derived MPNST cells was modest. All 
3 MPNST cell lines exhibited S-phase arrest when treated with either HDAC8i. Additionally, 
an increase in sub G1 population is observed (depicted in the respective histograms), 
suggesting cell death. 
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STS26T exhibited the greatest increase in PCI3/4-induced S-phase arrest with 
reductions in both G1 and G2 fractions. Despite the marked PCI3/4-induced increase 
in the S-phase fraction in STS26T, this increase was not statistically significant (p = 
0.1 and 0.09 for PCI3 and 4, respectively). In the cell lines tested, PCI4 was shown to 
induce a slightly higher increase in the S-phase fraction compared to PCI3. Both 
HDAC8is and especially PCI2 induced an increase in the sub-G1 fraction in NF1-
associated cells with a modest effect in sporadic MPNST cells. Since the sub-G1 
fraction potentially indicates apoptosis, we next evaluated the effect of both 
compounds on apoptosis. PCI3/4 induced marked apoptosis in human MPNST and 
murine-derived MPNST cells (Fig. 52) 
 
 
 
 
 
Figure 52. HDAC8i (PCI3/4 5uM/96 h) induced human MPNST cell apoptosis (Annexin 
V/PI staining FACS analyses). Similar to the “sensitive” and “resistant” pattern observed in 
Figure 23, NF1-associated cell line S462 showed marked HDAC8i-induced apoptosis 
while these effects were lower in sporadic cell lines. The response of these cell lines to 
HDAC8i-induced apoptosis was recapitulated and further confirmed via WB for cleaved 
caspase 3 (CC3). Due to the higher sensitivity toward HDAC8i compared to human 
MPNST cell lines, murine MPNST cells were treated for 48 h. PCI2 (0.5uM/48 h) and both 
HDAC8i (PCI3/4 5uM/48 h) induced marked apoptosis in murine-derived MPNST cells 
(Annexin V/PI staining FACS analyses, CC3 WB). 
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 PCI3 and PCI4 enhanced annexin V positive cells S462, where PCI4 had a 
significantly higher effect than PCI3 (p=0.29 and p=0.03 for PCI3 and 4, respectively). 
This enhancement of PCI3/4-induced apoptosis was confirmed via an increase in 
cleaved caspase 3 (CC3). PCI3 induced an increase in annexin V positive STS26T 
cells (p= 0.18) but a significant increase in annexin V positive STS26T cells (p= 0.03) 
was observed with PCI4 treatment. PCI3/4-induced apoptosis in STS26T cells was 
demonstrated when immunoblotting for cleaved caspase 3 (CC3). Murine-derived 
MPNST cells exhibited PCI2-induced as well as PCI3/4-induced apoptosis (48 h). All 
three drugs induced significant apoptosis in MPNST6IEP cells as depicted using 
Annexin V FACS analysis (PCI2, PCI3, and PCI4, p<0.05) and cleaved caspase 3 
(CC3) WB.  
These promising in vitro data supports the role of HDAC8 in MPNST warranting further 
investigation.  
 
5.2 Effects of PCI4 on the growth of human and murine MPNST in vivo 
To investigate the role of HDAC8 inhibition in vivo, we utilized our only human NF1-
associated MPNST model using MPNST642 cells. This experiment was conducted as 
mentioned above (Section 2.1 and ref. 56) while utilizing PCI4 (20 mg/kg BID) instead 
of PCI2. During the course of this therapeutic experiment, there was no discernible 
xenograft growth variation between the vehicle and PCI4-treated groups as tumors 
from both groups grew in parallel (Fig. 53). No noticeable drug-induced toxicities 
occurred as the mice remained in relatively good well-being with no weight loss. At  
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termination of this experiment, tumor volumes and weights were surprisingly 
marginally higher in PCI4-treated mice compared to vehicle-treated mice (PCI4-treated 
mice average tumor volume and weight: 1906.4 mm3 ±594.8 and 1.96 g ±0.52, 
respectively; vehicle-treated mice average tumor volume and weight: 1679.1 mm3 
±648.5 and 1.48 g ±0.43, respectively). To test if the lack of effect might be related to 
problems with drug accessibility plasma and tissue was collected and saved for future 
PK/PD analysis. This therapeutic experiment was repeated using the murine-derived 
MPNST6IEPVI cell line. This study was conducted similar to the previous experiment. 
Treatment with PCI4 began when palpable tumors reached an average diameter of 
~5mm. The growth rate of the MPNST6IEPVI xenografts was fast and thus treatment 
occurred for 12 days. Of note, two mice from the vehicle group and one mouse from 
the PCI4 treatment began to take on a thin appearance despite the absence of weight 
Figure 53. SCID mice bearing MPNST642 xenografts were treated with PCI4 (PCI4; 20 
mg/kg BID) or vehicle (5-6 mice/group). Tumor growth and weight curves are depicted 
showing that PCI4 had no effect on the growth of MPNST642 tumors. Tumors were 
processed for H&E. Serum and tumors were saved for PD/PK studies to identify drug 
concentration circulating in the mice and tumor. 
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loss. The abdomen of these thinning mice appeared larger than that of their litter 
mates. Aside from these three above-mentioned thin mice, all other mice in both 
groups appeared to be in good well-being. During the course and at termination of this 
experiment tumors from PCI4 therapy were noticeably small than vehicle-treated 
tumors (Fig. 54).  
 
 
 
 
 
 
 
 
 
 
PCI4 treatment significantly abrogated tumor volume and weight compared to vehicle 
(p= 0.001 and p= 0.02, respectively). At the end of this experiment the average tumor 
volume and weight for vehicle-treated mice was 2786.1 mm3 ±396 and 1.96 g ±0.28, 
respectively; and average tumor volume and weight for PCI4-treated mice was 1215.1 
mm3 ±125 and 1.21 g ±0.11, respectively. When tumors were collected, each mouse 
was dissected to evaluate potential spontaneous metastases. The stomach and 
intestine of both thin mice from the vehicle group and one thin mouse from the PCI4 
Figure 54. SCID mice bearing MPNST6IEPVI xenografts were treated with PCI4 (20 mg/kg 
BID) or vehicle (10 mice/group). Tumor growth and weight curves are depicted showing that 
PCI4 abrogated the growth of MPNST6IEPVI tumors (p = 0.001354 and 0.022833 for tumor 
size and weight, respectively). 
* statistically significant effects; p < 0.05. 
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group had numerous metastatic nodules of varying size. The lungs of these mice were 
also inspected during the dissection and were suspect of metastasis. Abdominal 
tumors and lungs from these mice were processed for H&E slides. 
This significant in vivo experiment supports further investigation and the attempt for an 
additional in vivo experiment utilizing a human MPNST cell line.  
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Chapter VII: Discussion  
 
These studies revealed important findings with great therapeutic potential. In these 
studies we showed the efficacy of pan-HDACi alone and in combination with 
conventional chemotherapy in genetically complex STS of various histologies in vitro 
and in vivo. Our findings supported the initiation of a clinical trial where PCI-24781 will 
be combined with doxorubicin for patients with advanced sarcoma (clinicaltrials.gov). 
Our focus then shifted to single histology, MPNST, where we demonstrated pan-
HDACi to have marked anti-MPNST effects in a cohort of NF1-associated MPNST 
cells lines in vitro and in vivo. In this study we also identified that our sporadic MPNST 
cell lines were relatively “resistant” to the pro-apoptotic effects of HDAC inhibition. 
HDACi-induced productive autophagy was identified as a mechanism of resistance in 
these cells, and when autophagy blockade was supplemented with HDAC inhibition, 
the cells succumbed to HDACi-induced apoptosis in vitro and in vivo. Among the 
HDACis currently tested clinically, they inhibit multiple HDAC isoforms, mainly class I 
HDACs. Despite their promise, the therapeutic index of these compounds is relatively 
low, given their wide spectrum of toxicities (95). By targeting a single, biologically 
relevant, HDAC isoform, our expectation was to improve therapeutic efficacy by 
reducing the toxicities associated with inhibition of multiple HDAC isoforms. Toward 
that end, we used HDAC8-specific inhibitors and tested their potential efficacy on 
human and murine-derived MPNST. Our initial data suggests a tumorigenic role 
HDAC8 in MPNST. We showed that, similar to T-cell derived leukemia (68) and 
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neuroblastoma cells (71), our human and murine-derived MPNST cells were sensitive 
to HDAC8 inhibition (doses around 5uM). Both human and murine NF1-associated 
MPNST exhibited more sensitivity to HDAC8 inhibition compared to human sporadic 
MPNST cells; an observation we previously reported with pan-HDAC inhibitors (56). 
Uniquely, all MPNST cell lines tested (both human and murine) exhibited HDAC8i-
induced S-phase cell cycle arrest. Most importantly, we demonstrated that HDAC8 
inhibition induced significant murine-derived MPNST xenograft growth inhibition in 
vivo. As these studies continue to expand, various aspects of these studies harbor 
intriguing queries. 
 
Similar to data in our study (50), the synergism among various HDACis combined with 
several anti-cancer compounds have been well documented in a variety of 
histologically diverse cancers. The synergistic effect usually depends on the 
sequencing of the compounds, where pre-treatment with an HDACi sensitizes tumors 
cells to the pro-apoptotic effects of chemotherapy. This sequencing enhanced the anti-
STS effects of doxorubicin and cisplatinum in both our in vitro and in vivo studies. 
Currently, there are more than 100 clinical trials evaluating the effects of HDACis 
combined with a variety of chemotherapies (www.clinicaltrials.gov). 
 
The HDACi-induced impairment of the double-strand break repair mechanism 
supplemented with DNA damaging compounds has been shown to have a synergistic 
role (96, 97). HDACis have been shown to inhibit HR repair, a potential mechanism 
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contributing to chemoresistance in some malignancies (96-98). Previously, our lab has 
shown the high expression of Rad51 is high in a variety of clinical and cell line STS 
subtypes. This overexpression of Rad51, a protein that plays a crucial role in HR, in 
STS potentially plays a role in their chemoresistant nature. When we knocked down 
(siRNA) Rad51, the STS cells tested succumbed to the pro-apoptotic effects of 
doxorubicin (85). Adimoolam and colleagues (98) have previously showed that PCI-
24781 reduced the expression of Rad51 in a colorectal carcinoma cell line (HCT116). 
PCI2-induced down-regulation of Rad51 inhibited HR and radiosensitized these 
colorectal carcinoma cells as well as lung carcinoma cell lines (NCI-H460, A549) to 
irradiation.  
In our study, we showed that PCI2 reduced the mRNA and protein expression of 
Rad51 in STS cells of different histology. We showed the PCI2-induced transcriptional 
repression of Rad51 to be mediated through increased binding of E2F1 to the Rad51 
proximal promoter. E2F1 has been shown to primarily act as a transcriptional activator, 
where E2F4 acts as a negative transcriptional regulator. Interestingly, Bindra and 
Glazer (99) have shown that during hypoxic conditions, E2F4/p103 complexes binds to 
the Rad51 promoter resulting in its downregulation. A negative regulatory role for 
E2F1 has also been described in a variety of genes (100-102). Possibly, E2F binding 
partners influence the positive or negative role on transcription, where HDACi can 
impact the construction of the E2F complexes. HDACis may also induce the 
acetylation of E2F proteins, thus enhancing their binding to their respective binding 
sites on various promoters (103). Despite these intriguing pre-clinical findings, DNA 
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damage repair does not solely depend on Rad51, as this dynamic mechanism utilizes 
numerous other molecules.  
 
Other genes (i.e. CHK1, CTGF) identified from our initial gene array may possibly 
contribute to the chemoresistant nature of STS. Gene array analysis showed that 
CTGF increased by an average of 16-fold and CHK1 decreased by an average of 6-
fold after PCI2 treatment. The PCI2-induced reduction of RNA and protein were 
confirmed for both genes. Lee et al. previously showed that SAHA induced DNA 
breaks in both normal as well as transformed cells, where normal cells retained the 
ability to repair the HDACi-induced DNA breaks (81). They showed that when CHK1 
was inhibited in vitro and in vivo in normal cells, the cells succumbed to the pro-
apoptotic effects of HDACi. The role of CHK1 on chemoresistance has been 
supplemented in a variety of studies combining CHK1 inhibition, either by genetic or 
chemical inhibition, with a variety of targeted therapies and chemotherapeutic 
compounds (104-106). Furthermore, cells with non-functional CHK1 have been shown 
to be sensitive to a vast range of DNA damaging compounds or replication inhibitors 
(107).  
Regarding the role of CTGF, there is evidence that CTGF regulates cancer cell 
migration, invasion, angiogenesis, and anoikis. However, CTGF has been associated 
with a favorable as well as unfavorable prognosis (108-111). Alterations of CTGF 
expression in tumor cells suggests that it may be regulated by epigenetic modifications 
of the DNA. Most array data did not suggest CTGF to be regulated by HDACs, 
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whereas a variable degree of up-regulation was observed in certain hepatoma cell 
lines (112) as well as our STS cell lines. Komorowsky et al. reported upregulation of 
CTGF in renal cell carcinoma cell lines and Hep3B cells upon treatment with various 
types of HDACis (113). These observations indicate that, in addition to the acetylation 
status of the histones, CTGF expression will be determined by cell type-specific 
transcription factors, which are direct or indirect targets of HDACs (114). 
CTGF has also been shown to serve a tumor suppressor. It can induce apoptosis in 
human breast cancer cells (108) and suppress cell proliferation in non–small cell lung 
cancer cells (109) and human oral squamous cell carcinoma–derived cells (110). 
Furthermore, studies have shown that lower CTGF expression was negatively 
associated with survival and mortality in lung adenocarcinoma and colorectal cancer 
(115, 111). Again, the biological function of CTGF seems to be cell type specific and it 
is probably due to the complex contextual interactions within a specific tumor 
environment (114).  
 
The basis for the selective toxicity of cancer cells to HDACis is not known. If aberrant 
gene expression were the primary method for HDACi-induced apoptosis, then it would 
be expect both normal cells and tumor cells to be equally sensitive to HDACis. As a 
matter of fact, providing that the disruption of apoptotic pathways is a critical 
occurrence in tumorigenesis, it would be anticipated that normal cells would be much 
more sensitive to HDACi-induced cell death than cancer cells. If HDACi-induced cell 
death is associated with aberrant mitosis, then the circumstance where cancer cells 
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generally lose their cell cycle checkpoints can make these cancer cells more sensitive 
to HDAC inhibition (117). The failure to activate two cell-cycle checkpoints that are 
present in normal cells is responsible for the tumor-selective action of HDACi (117).  
In the context of sensitivity to HDACis, we previously showed that NF1-associated 
MPNST are relatively more sensitive to HDACi compared to sporadic MPNST cells. In 
the natural history of MPNST, the loss of NF1 is a hallmark of the disease. This Ras-
GAP protein regulates the activity of various Ras isoforms (K-, H-, and N-Ras). The 
loss of this gene results in higher Ras activity consequentially promoting tumor survival 
and progression. In our study, we showed that NF1-associated MPNST cells were 
more sensitive to the pro-apoptotic effects of HDACis compared to sporadic MPNST 
cell lines. Sporadic MPNST can manifest in the presence or somatic loss of NF1 (24). 
Currently, the precise occurrence and importance of the somatic loss of NF1 in 
sporadic MPNST progression is unknown. We showed that both sporadic cells, 
STS26T and MPNST724 had NF1. Using a Ras activity assay, STS26T had no Ras 
activity, however, despite the presence of NF1, Ras activity was enhanced in 
MPNST724. Despite the Ras activity in one sporadic cell lines and not the other, 
knockdown of NF1 in both cell lines sensitized the cells to the pro-apoptotic effects of 
HDACi. The tumor suppressive role of NF1 is well documented, however, at least in 
our study, its loss sensitizes sporadic MPNST cells to HDAC inhibition. Interestingly, 
enhanced Ras activity has been shown to sensitize STAT1-deficient cells to pan-
HDACi-induced apoptosis (118).However, regardless of enhanced Ras activity in 
MPNST724, the cells succumbed to HDACi-induced apoptosis with NF1 knock down, 
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suggesting a potential protective role of NF1 outside of its regulatory role in Ras 
activation. In a non-Ras-GAP role, NF1 overexpression has been shown to induce an 
increase in the expression levels of the focal adhesion kinase (FAK), and changes in 
the activation mitogen-activated protein kinases proteins (MAPKs) (119). This 
suggests the presence of a Ras-independent NF1-dependent pathway able to modify 
the levels of expression of FAK and the levels of activation of MAPKs. Because FAK 
and many proteins recently found to bind NF1 have a role in the cytoskeleton, this 
pathway may involve rearrangement of cytoskeletal components that assist in 
anchorage independence (120). NF1 knockout has been shown to activate the Rho-
ROCK-LIMK2-cofillin pathway to modify the actin cytoskeleton reorganization and 
stimulate cell motility, invasiveness, and cell-cell adhesion, thus leading to the 
formation of large cell aggregates. This phenotype is suggestive toward the multiple 
neurofibroma formations in NF1 patients (120). From this, it would be interesting to 
identify if this pathway is constitutively active in our NF1-associated compared to our 
sporadic MPNST cell lines. Activation of this pathway may also explain the presence 
of potential spontaneous metastases observed in our MPNST6IEPVI in vivo model. 
Identifying the potential activation of this pathway in NF1-associated MPNST and 
correlating its activation with metastases may rationalize novel combination 
therapeutic strategies for metastatic disease in NF1 patients.  
Where a majority of cancer cells tested exhibit sensitivity to pan-HDACis, normal cells 
show resistance. As briefly mentioned before, the accumulation of reactive oxygen 
species (ROS) is among the many mechanisms of HDACi-induced sensitivity in cancer 
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cells (121-123). Unlike cancer cells, normal cells exhibit a higher expression of 
thioredoxin, a natural scavenger of ROS; potentially playing a role in their resistance to 
pan-HDACi-induced oxidative stress. This cytoprotective role of thioredoxin to pan-
HDACi was established where knockdown of thioredoxin sensitized normal cells to the 
pro-apoptotic effects of pan-HDACi (124). Certain cancer cells overexpress 
thioredoxin, potentially giving them a survival advantage toward HDACi-induced 
oxidative stress (125, 126). Similar to the effects observed in normal cells, inhibition or 
knockdown of this antioxidant in these cancers can enhance the efficacy of pan-
HDACis, potentially making this combination therapy ideal in cancer exhibiting 
resistance to HDACis. Pre-clinical screening of tumors with an up-regulation of 
thioredoxin would likely denote their probable response to HDACi. As of note, 
Subramanian et al., showed that Bax-/- embryonic murine fibroblasts to be resistant to 
pan-HDAC inhibition (127).  
Other mechanisms of resistance toward HDACis have been documented and 
summarized by Fantin and Richon (128). One such mechanism of therapeutic 
resistance is therapy-induced autophagy. 
 
In our study, we identified HDACi-induced productive macroautophagy (herein 
“autophagy”) as a mode of resistance in MPNST cells in vitro and in vivo.  
Autophagy is an intracellular, catabolic process used to degrade and recycle cellular 
components via the lysosomal system (129). Autophagy is a dynamic process that 
plays an integral role in normal processes maintaining cellular homeostasis. Various 
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forms of autophagy have been identified. The bulk, lysosomal-mediated degradation of 
long-lived proteins and long-lived/damaged organelles occurs through 
macroautophagy. Where macroautophagy is the most studied mechanism, other forms 
of autophagy exist: microautophagy is the direct engulfment of cellular constituents by 
the lysosome; chaperone-mediated autophagy occurs where only proteins that 
possess a certain peptidic consensus sequence are identified by a chaperone complex 
and moved to the lysosome. Numerous forms of selective autophagy have also been 
identified: pexophagy (selective degradation of peroxisomes), mitophagy (selective 
degradation of mitochondria), aggrephagy (selective degradation of proteins 
aggregates), xenophagy (selective degradation of foreign bodies; i.e. bacteria, viruses) 
are among the various forms of selective autophagy (130). 
When studying autophagy, the detection of autophagosome accumulation does not 
translate to an increase in autophagic flux. Klionsky et al., have emphasized the utility 
of “multiple assays” to properly identify the presence of autophagy as well as the 
functionality of this process (79).  
Autophagic flux or productive autophagy refers to the complete, unperturbed process 
of autophagy beginning with the development of a horseshoe-shaped double 
membranous phagophore, which develops around an area of cytoplasmic contents 
enclosing the contents in an autophagosome which is then fused with a lysosome at 
which the autophagosomal contents are degraded where these degraded components 
can be reused by the cell (129). Aside from the homeostatic role of autophagy in 
normal cell physiology, autophagic cell death (ACD, type II cell death) was previously 
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suggested as a mode of cell death (131, 132). ACD has been suggested as a 
misnomer (133) where cell death with autophagy is the likely occurrence 
notwithstanding, the archival evidence recently brought forth by Clarke and Puyal that 
bone fide autophagic cell death (cell death promoted via autophagy, independent from 
apoptosis or necrosis) occurs in some contexts (134). Shao and colleagues showed 
that HDAC inhibitors SAHA and butyrate induced cell death that had morphological 
features of autophagy, independent of caspase activation in Apaf-1 KO MEF cells, 
HeLa cells overexpressing Bcl-XL, and cells treated with caspase inhibitor Z-VAD-
FMK (122). In our studies, we demonstrated that NF1-associated MPNST cells 
succumbed to HDACi-induced apoptosis. In the apoptotic bodies of these cells, 
numerous autophagosomal structures were identified, suggesting, at least in our 
model, that HDAC inhibition induces apoptosis in the presence of autophagy. Although 
not yet attempted in our studies, it would be interesting to investigate the outcome of 
apoptosis inhibition combined with HDAC inhibition in our MPNST models (e.g. 
caspase inhibitor Z-VAD-FMK combined with HDACi). The cross-talk among the 
autophagic and cell death pathways is well established (135). For instance, Pyo and 
colleagues showed that ATG5, a protein important during formation of the extending 
autophagosomal membrane, interacts with Fas-Associated protein with Death Domain 
(FADD) to induce interferon-γ-mediated cell death in HeLa cells (136). Furthermore, 
Yousefi et al. demonstrated that ATG5 can be cleaved in a calpain-dependent manner, 
resulting in a “switch” from autophagy to apoptosis (137). Although not yet studied in 
our NF1-associated MPNST model, the presence of numerous autophagosomal 
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structures in HDACi-induced apoptotic bodies (Fig. 32) suggests the aforementioned 
cross-talk among these dynamic processes; NF1-associated cells were succumbing to 
HDACi-induced apoptosis in the presence of autophagy, rather than dying of 
autophagic cell death.  
While the controversy between ACD and the therapy-induced protective role remains, 
a majority of studies have pointed out that anti-cancer therapy-induced autophagy 
serves in the survival of cancer cells (138-140).  
The deregulation of autophagy-related genes has been shown to augment 
tumorigenesis in some malignancies (141). In the case of many breast-related 
malignancies, BECN1 is monoallelically deleted resulting in deregulated autophagy 
(142, 143), indicating the tumor suppressive role of autophagy. Tumor cells with 
functional autophagic machinery can circumvent cell death potentially manifested in 
the form of anti-cancer therapy or bio-energetic stress (144).   
 
As in the case with our work in MPNST, a wide variety of studies have shown tumor 
growth inhibition and the augmentation of cell death when therapies that induce 
autophagy are initially supplemented with the inhibition of autophagy (145-147).  
A variety of methods, either being genetic or pharmacological inhibition are used to 
study the effects of autophagy inhibition. With current methods, autophagy can be 
inhibited at induction or the early steps of the formation of the autophagosome and at 
the stage of lysosomal-mediated degradation. Tumors cells that use therapy-induced 
autophagy as a mode of resistance; inhibition at either of the abovementioned stages 
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of autophagy enhances tumor cell growth inhibition and cell death. We showed that 
regardless of autophagic stage inhibition, either by inhibiting induction with Beclin1 or 
ATG5/7 siRNA or by inhibiting lysosomal-mediated degradation with chloroquine or 
BFA, the pro-apoptotic effects of HDACi in MPNST were enhanced in vitro and in vivo. 
Our data enhanced the current knowledge and importance of therapy resistance 
mediated through therapy-induced autophagy, and further complements the impetus 
toward the inhibition of autophagy in the clinical setting.  Among the compounds used 
to inhibit autophagy, chloroquine and its derivatives are currently the only autophagy 
inhibitors used in the clinic. While chloroquine has been used for the treatment of 
malaria and is currently being used in clinical trials as an autophagy inhibitor, this 
compound has some off- target effects outside of autophagy (147). The lack of 
autophagy-specific inhibitors for clinical use warrants the development and/or 
identification of novel inhibitors which may support the role of autophagy in the context 
of cancer therapy. The identification/development of novel autophagy inhibitors can 
potentially lead to the clinically relevant development of novel combination therapies 
beyond the current, sole use of chloroquine. It is important to form an understanding 
regarding the selective manipulation of autophagy in therapeutically specific 
circumstances. In our studies we showed that HDACi induces the expression of IRGM, 
TMEM74, and CXCR4 potentially contributing the HDACi-induced autophagy observed 
in our MPNST cells. While the role of autophagy in these proteins has been identified 
(148-150), their individual role in the autophagic machinery and contribution toward 
HDACi-induced autophagy and chemoresistance remains to be discovered. As a proof 
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of concept, we showed that when IRGM was genetically inhibited by siRNA, HDACi-
induced autophagy was blocked leading to the increase of HDACi-induced apoptosis. 
As this initial pre-clinical data is forthcoming, it will be important to expand these 
studies further with the hopes of potentially identifying “druggable” targets in a novel 
manner to inhibit autophagy. 
 
It will also be important to identify the role of HDAC inhibition on these inducible 
targets; which individual HDAC or combination of HDAC isoforms induces autophagy, 
and which of these scenarios induce the expression of certain genes (i.e. IRGM, 
TMEM74, CXCR4) that induce autophagy? Identifying these specificities will broaden 
the current, yet limited knowledge on the aforementioned subject with efforts geared 
toward clinical practicality.    
 
Where we showed the significant anti-STS and anti-MPNST effects exerted by pan-
HDACis, we also began initial studies observing the effects by inhibiting individual 
HDAC isoforms, namely HDAC8. In the milieu of normal human tissues, HDAC8 has 
been shown to be exclusively expressed by cells showing smooth muscle 
differentiation, including visceral and vascular smooth muscle cells, myoepithelial cells, 
and myofibroblasts, and is mainly detected in the cytosol (66). Waltregny et al. showed 
that HDAC8 overexpression in murine fibroblasts formed cytoplasmic stress fiber-like 
structures that co-localized with the smooth muscle cytoskeleton protein smooth 
muscle α-actin. 
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HDAC8 has also been shown to potentially be a more sensitive marker than desmin 
and h-caldesmon in epithelioid smooth muscle tumors, where HDAC8 detection may 
be useful in serving in the differential diagnosis of uterine-derived mesenchymal 
tumors (67). As these studies have identified the practical use of HDAC8 clinically, little 
is known about molecular contributions in normal and cancer cells. The identification of 
acetylated targets of HDAC8 has been very minimal. Recently, Karolczak-Bayatti and 
colleagues showed HDAC8 can interact with Hsp20 to affect its acetylation (151). In 
their study they used a HDAC8 inhibitor that augmented Hsp20 acetylation with no 
increase of histone acetylation or discernible global gene expression changes. The 
effects they observed were associated with significant inhibition of spontaneous and 
oxytocin-augmented contractions of ex vivo human myometrial tissue strips. A 
possible mechanism by which Hsp20 acetylation can affect myometrial activity is by 
the liberation of cofilin, which will regulate contraction in smooth muscle cells (151). 
A notable observation in our study was HDAC8i-induced increase in the S-phase in 
human and murine-derived MPNST cells regardless of their NF1 and p53 status. This 
unique cell cycle arrest occurred with both HDAC8 inhibitors (PCI3 and PCI4) whereas 
pan-HDACi induced either G1- or G2-cell cycle arrest in sporadic and human and 
murine-derived NF1-associated MPNST cells.  
 
S-phase checkpoint has been shown to be mediated by ATR and Chk2 in human cells 
in response to DNA damage and replication-stress conditions (152). The S-phase 
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checkpoint can be categorized into three checkpoints: replication, S-M, and intra-S-
phase checkpoint. The replication checkpoint initiates when the replication forks get 
stalled due to a stress (i.e. depletion of dNTP pools, inhibition of DNA polymerases, 
DNA damage). S-M checkpoint certifies that cells wont attempt to divide before the 
whole genome becomes duplicated. DNA double-strand breaks which are created just 
outside the active replicon activates the the intra-S-phase checkpoint. Unlike the other 
two S-phase checkpoints, this checkpoint does not get activated in response to 
disruption at the replication fork.   
 
Notably, none of the S-phase checkpoints require p53 (153, 154) for their activation.  
As we have yet identified a role for HDAC8 during S-phase of the cell cycle, Deardorff 
and colleagues recently reported that structural maintenance of chromosomes 3 
(SMC3) is a deacetylation target of HDAC8 in HeLa cells (155). SMC3 is a member of 
the SMC family of proteins (156, 158). This protein is a vital component of a multi-
protein cohesin complex that holds sister chromatids together during mitosis, 
facilitating proper segregation of the chromosome (156). Acetylation of SMC3 has 
been shown to occur and play an essential role during S-phase in both yeast and 
human systems (158). Where we have shown possible S-phase arrest after treatment 
with PCI3/4, Deardorff et al., showed unaltered cell cycle progression in HeLa cells in 
the presence of HDAC8 inhibition (i.e. inhibition of HDAC8 was performed using 
siRNA and/or 25uM, PCI-34051). Identification of this HDAC8-SMC3 interaction 
among other potential HDAC8 regulated S-phase proteins will enhance current 
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knowledge on the role of HDAC8 in cell cycle progression. It will also be essential to 
determine the effect of HDAC8 inhibition on the cell cycle progression of normal cells. 
If HDAC8 inhibition induces bona fide S-phase arrest in MPNST cells, it may be ideal 
to combine HDAC8 inhibition with antimetabolitic compounds (e.g. 5-fluorouracil, 
cytarabine, gemcitabine, etc.), which exert their cytotoxic effects during S-phase. 
 
This is but one aspect on the role of HDAC8 in genetically complex STS as we plan to 
continue to develop our basic knowledge on this subject. This study has led to 
invaluable information that not only enhances current knowledge on the biology of 
genetically complex STS, namely MPNST, but also the impetus for novel therapies for 
patients with these malignancies.  
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Chapter VIII: Conclusions and future directions 
 
      In this work we have shown the therapeutic efficacy of pan-HDACis in combination 
with chemotherapy for the treatment of complex karyotypic STS. Our initial study 
(Lopez et al. 2009) helped support the rational that lead to a clinical trial combining 
PCI2 with conventional chemotherapy for patients with high grade STS.  
Similar to the anti-STS effect of pan-HDACis in STS cells of various histology, pan-
HDACis were shown to have a significant anti-MPNST effect in NF1-associated, but 
not in sporadic MPNST. This dichotomy among the NF1-associated and sporadic 
MPNST cohorts lead us to the identification of HDACi-induced productive autophagy; 
an implied mechanism of therapeutic resistance observed in a variety of pre-clinical 
and clinical settings. Inhibition of HDACi-induced productive autophagy enhanced the 
pro-apoptotic effects of HDACi in vitro and in vivo. These data opened a variety of 
current and future avenues exploring the vast role HDAC inhibition and the 
contribution toward anti-STS effects. One such avenue was to identify the role of 
individual HDAC isoforms in STS. The unique pattern of “sensitivity” and “resistance” 
to pan-HDACi in our MPNST model lead us to further dissect this distinction based on 
the contribution of class I HDAC isoforms. Of the class I HDAC isoforms, due to its 
unique catalytic structure compared to other HDACs of this class (i.e. HDAC1, 2, 3), 
HDAC8-specific inhibitors have been developed. To elucidate the contribution of 
individual HDACs in MPNST we utilized HDAC8-specific inhibitors in vitro and in vivo. 
Initial data demonstrated that both HDAC8 inhibitors abrogated human and murine-
derived MPNST cell growth by uniquely inducing S-phase arrest and inducing cell 
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death in vitro. Most importantly, HDAC8 inhibition significantly abrogated murine-
derived MPNST xenograft growth in vivo.  
 
Future studies will be to identify the expression of HDAC8 in normal nerve, 
neurofibroma, and MPNST clinical samples (TMA) to distinguish a possible correlation 
with the progression of the disease. HDAC8 has been reported to be a nuclear as well 
as cytoplasmic protein. As briefly mentioned above, knowledge of its role in either 
cellular compartment is limited and is cell context specific. Determining the sub-cellular 
localization of HDAC8 in clinical samples as well as tumor cells lines will be 
translationally pertinent.  Preliminary effects reported in this study using the HDAC8 
inhibitors will be supplemented with the utility of siRNA, specific for HDAC8. Taking 
into consideration of future studies, inhibiting HDAC8 with either siRNA or compound 
may yield variations in biological outcome. Pharmacological inhibition of HDAC8 will 
inhibit the enzymes ability to deacetylate its targets, however, this inhibitory method 
may not disrupt functional multi-protein complex potentially containing HDAC8. siRNA 
targeting HDAC8 would not only inhibit deacetylation of its targets, but it would also 
disrupt multi-protein complexes where HDAC8 plays a role. With the aforementioned 
scenario in mind, the potential identification of binding partners and acetylation targets 
of HDAC8 will also be explored using both siRNA and PCI3/4 in high throughput 
experiments. This method will be carried out by isolating acetylated proteins after 
HDAC8 inhibition followed by mass spectrometry analysis. Furthermore, gene 
expression patterns correlating with therapeutic response will be established. To 
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further complement the experiments proposed above and identify potential gene 
expression signatures predictive of HDAC8 inhibition response as well as HDAC8 
inhibition-induced gene expression changes that might correlate with enhanced 
therapeutic response gene array analysis on control and HDAC8-inhibition-treated 
cells (siRNA and PCI3/4) will be performed. 
Potential studies mentioned above will hopefully demonstrate significant efficacy of 
HDAC8 inhibitors in MPNST preclinical models, thus forming a basis for design of 
‘smart’ personalized, and future STS clinical trials. HDAC8 is an understudied HDAC 
isoform; comprehensive investigation to determine HDAC8 expression, localization, 
function and molecular driven mechanisms is unequivocally warranted. 
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